ABT-737

For research use only. Not for use in humans.

目录号：S1002

CAS No. 852808-04-9

ABT-737是一种BH3模拟抑制剂，作用于Bcl-xL，Bcl-2和Bcl-w，无细胞试验中EC50分别为78.7 nM，30.3 nM和197.8 nM；但对Mcl-1， Bcl-B及Bfl-1没有抑制作用。ABT-737可诱导线粒体通路的凋亡和线粒体自噬。Phase 2。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 3144.65	现货
5mg	RMB 972.14	现货
50mg	RMB 4659.22	现货
100mg	RMB 7964.03	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的ABT-737发表文献317篇：

Cell, 2018, 175(2):429-441

PubMed: 30245008 ( click the link to review the publication )

Cancer Cell, 2018, 33(3):435-449

PubMed: 29533784 ( click the link to review the publication )

Nature, 2017, 551(7679):247-250

PubMed: 29088702 ( click the link to review the publication )

Nat Methods, 2017, 14(9):891-896

PubMed: 28737741 ( click the link to review the publication )

Nature, 2016, 529(7586):413-417

PubMed: 26735014 ( click the link to review the publication )

Nat Med, 2013, 19(11):1478-88

PubMed: 24141421 ( click the link to review the publication )

Nat Biotechnol, 2011, 29(6):542-6

PubMed: 21623355 ( click the link to review the publication )

Cell Death Dis, 2021, 12(8):736

PubMed: 34312366 ( click the link to review the publication )

Cell Death Dis, 2021, 12(8):784

PubMed: 34381022 ( click the link to review the publication )

J Infect, 2021, S0163-4453(21)00200-0

PubMed: 33892015 ( click the link to review the publication )

Int J Mol Sci, 2021, 22(10)5405

PubMed: 34065600 ( click the link to review the publication )

Adv Biol Regul, 2021, S2212-4926(20)30091-9

PubMed: 33451973 ( click the link to review the publication )

Commun Biol, 2021, 4(1):20

PubMed: 33398046 ( click the link to review the publication )

ACS Nano, 2020, 14(3):3378-3388

PubMed: 32083466 ( click the link to review the publication )

Sci Adv, 2020, 6(47)eabc3465

PubMed: 33208362 ( click the link to review the publication )

Nat Commun, 2020, 11(1):259

PubMed: 31937780 ( click the link to review the publication )

Sci Adv, 2020, 6(34):eaba8968

PubMed: 32937365 ( click the link to review the publication )

EMBO J, 2020, e105071

PubMed: 32840892 ( click the link to review the publication )

Cancer Res, 2020, 10.1158/0008-5472.CAN-19-1784

PubMed: 32005716 ( click the link to review the publication )

Elife, 2020, 2;9:e54954

PubMed: 32484436 ( click the link to review the publication )

Cancers (Basel), 2020, 10;12(2) pii: E406

PubMed: 32050632 ( click the link to review the publication )

Cancer Discov, 2020, CD-20-0756

PubMed: 33334730 ( click the link to review the publication )

Development, 2020, 147(22)dev194555

PubMed: 33028610 ( click the link to review the publication )

Mol Cancer Ther, 2020, 5;molcanther.510.2019

PubMed: 32371581 ( click the link to review the publication )
Allergy Asthma Immunol Res, 2020, 12(4):608-625

PubMed: 32400128 ( click the link to review the publication )

Mol Cancer Res, 2020, 10.1158/1541-7786.MCR-19-0669

PubMed: 32238439 ( click the link to review the publication )

Front Mol Biosci, 2020, 7:566291

PubMed: 33425984 ( click the link to review the publication )

Sci Rep, 2020, 20;10(1):687

PubMed: 31959760 ( click the link to review the publication )

Cancer Cell Int, 2020, 20:405

PubMed: 32863764 ( click the link to review the publication )

Biomed Pharmacother, 2020, 126:110040

PubMed: 32145585 ( click the link to review the publication )

Ann Transl Med, 2020, 8(6):364

PubMed: 32355808 ( click the link to review the publication )

Eur J Pharm Sci, 2020, 142:105105

PubMed: 31669390 ( click the link to review the publication )

Platelets, 2020, 10.1080/09537104.2020.1724276

PubMed: 32079453 ( click the link to review the publication )

Cell Death Differ, 2020, 10.1038

PubMed: 32015503 ( click the link to review the publication )

Environ Toxicol, 2020, 10.1002

PubMed: 32061152 ( click the link to review the publication )

Cell Rep, 2020, 32(1):107845

PubMed: 32640215 ( click the link to review the publication )

Life Sci Alliance, 2020, 28;3(6) pii: e202000735

PubMed: 32345661 ( click the link to review the publication )

Transfusion, 2020, 60(4):806-814

PubMed: 32159862 ( click the link to review the publication )

PLoS One, 2020, 15(7):e0234103

PubMed: 32645016 ( click the link to review the publication )

Infect Immun, 2020, 10.1128/IAI.00851-19

PubMed: 32179584 ( click the link to review the publication )

Aging (Albany NY), 2020, 12(14):14174-14188

PubMed: 32692721 ( click the link to review the publication )

STAR Protoc, 2020, 1(1)100034

PubMed: 32793892 ( click the link to review the publication )

Cell Death Dis, 2020, 11(1):8

PubMed: 31907357 ( click the link to review the publication )

Mol Cell, 2019, 74(1):19-31

PubMed: 30878284 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5770

PubMed: 31852899 ( click the link to review the publication )

EMBO J, 2019, 15;38(10):e101638

PubMed: 30902848 ( click the link to review the publication )

EMBO J, 2019, 38(11)

PubMed: 30979778 ( click the link to review the publication )

Dev Cell, 2019, 51(2):277-291

PubMed: 31564612 ( click the link to review the publication )
Cancer Res, 2019, 79(9):2339-2351

PubMed: 30862722 ( click the link to review the publication )

Cell Rep, 2019, 27(12):3657-3671

PubMed: 31216482 ( click the link to review the publication )

Cell Rep, 2019, 27(3):820-834

PubMed: 30995479 ( click the link to review the publication )

Elife, 2019, 8e38730

PubMed: 31042147 ( click the link to review the publication )

Br J Pharmacol, 2019, 176(3):436-450

PubMed: 30427531 ( click the link to review the publication )

Cancers (Basel), 2019, 11(9)

PubMed: 31540244 ( click the link to review the publication )

Cancers (Basel), 2019, 11(12)

PubMed: 31810230 ( click the link to review the publication )

Cell Death Dis, 2019, 10(2):121

PubMed: 30741926 ( click the link to review the publication )

J Cancer, 2019, 10(6):1466-1478

PubMed: 31031856 ( click the link to review the publication )

Thromb Haemost, 2019, 19(10):1665-1674

PubMed: 31493778 ( click the link to review the publication )

Oxid Med Cell Longev, 2019, 2019:5820415

PubMed: 31885804 ( click the link to review the publication )

Eur J Immunol, 2019, 10.1002/eji.201948254

PubMed: 31411729 ( click the link to review the publication )

Sci Rep, 2019, 9(1):1897

PubMed: 30760778 ( click the link to review the publication )

Mol Pharmacol, 2019, 96(4):419-429

PubMed: 31467029 ( click the link to review the publication )

Biochem J, 2019, 476(9):1335-1357

PubMed: 30992316 ( click the link to review the publication )

Phytomedicine, 2019, 64:153068

PubMed: 31419729 ( click the link to review the publication )

Phytomedicine, 2019, 52:147-156

PubMed: 30599894 ( click the link to review the publication )

Life Sci, 2019, 232:116561

PubMed: 31247208 ( click the link to review the publication )

Chem Biol Interact, 2019, 309:108723

PubMed: 31228469 ( click the link to review the publication )

J Bone Oncol, 2019, 19:100268

PubMed: 31832331 ( click the link to review the publication )

J Bone Oncol, 2019, 15:100222

PubMed: 30766792 ( click the link to review the publication )

PLoS One, 2019, 14(12):e0225977

PubMed: 31826021 ( click the link to review the publication )

Onco Targets Ther, 2019, 12:897-906

PubMed: 30774376 ( click the link to review the publication )

Platelets, 2019, 30(1):75-80

PubMed: 29125379 ( click the link to review the publication )
Oncotarget, 2019, 10(58):6219-6233

PubMed: 31692812 ( click the link to review the publication )

Am J Respir Crit Care Med, 2019, 200(1):84-97

PubMed: 30649895 ( click the link to review the publication )

Immunity, 2018, 48(4):675-687

PubMed: 29653696 ( click the link to review the publication )

Nat Commun, 2018, 9(1):5435

PubMed: 30575733 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(21):5458-5470

PubMed: 30021909 ( click the link to review the publication )

Cell Death Differ, 2018, 25(4):784-796

PubMed: 29229994 ( click the link to review the publication )

Oncogene, 2018, 37(39):5325-5339

PubMed: 29858601 ( click the link to review the publication )

Oncogene, 2018, 37(33):4599-4610

PubMed: 29755130 ( click the link to review the publication )

Cell Mol Life Sci, 2018, 75(14):2663-2680

PubMed: 29396625 ( click the link to review the publication )

Cancers (Basel), 2018, 10(11)E439

PubMed: 30441794 ( click the link to review the publication )

Cell Death Dis, 2018, 9(10):944

PubMed: 30237504 ( click the link to review the publication )

Cell Death Dis, 2018, 9(2):123

PubMed: 29374144 ( click the link to review the publication )

Cell Death Dis, 2018, 9(10):994

PubMed: 30250198 ( click the link to review the publication )

Cell Death Dis, 2018, 9(2):199

PubMed: 29415991 ( click the link to review the publication )

Cell Death Dis, 2018, 92(10)

PubMed: 23640461 ( click the link to review the publication )

Cell Physiol Biochem, 2018, 48(3):1123-1138

PubMed: 30041196 ( click the link to review the publication )

Eur J Med Chem, 2018, 159:357-380

PubMed: 30308410 ( click the link to review the publication )

Biochim Biophys Acta Mol Cell Res, 2018, 1865(3):522-531

PubMed: 29278689 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(6):935-946

PubMed: 29545477 ( click the link to review the publication )

Antioxidants (Basel), 2018, 10.3390/antiox7110150

PubMed: 30373097 ( click the link to review the publication )

Sci Rep, 2018, 8(1):15752

PubMed: 30361682 ( click the link to review the publication )

Int J Oncol, 2018, 53(3):1055-1068

PubMed: 30015875 ( click the link to review the publication )

Cancer Biol Ther, 2018, 19(6):465-474

PubMed: 29394130 ( click the link to review the publication )

Phytother Res, 2018, 32(6):1126-1134

PubMed: 29464855 ( click the link to review the publication )
Thromb Res, 2018, 171:22-30

PubMed: 30240944 ( click the link to review the publication )

Environ Mol Mutagen, 2018, 59(1):49-59

PubMed: 28843007 ( click the link to review the publication )

Ann Surg Treat Res, 2018, 95(5):240-248

PubMed: 30402442 ( click the link to review the publication )

Oncotarget, 2018, 9(28):20075-20088

PubMed: 29732004 ( click the link to review the publication )

Oncotarget, 2018, 9(24):16701-16717

PubMed: 29682179 ( click the link to review the publication )

Oncotarget, 2018, 9(39):25630-25646

PubMed: 29876013 ( click the link to review the publication )

Oncotarget, 2018, 9(42):26834-26851

PubMed: 29928488 ( click the link to review the publication )

Nat Cell Biol, 2017, 19(10):1226-1236

PubMed: 28945232 ( click the link to review the publication )

Nat Cell Biol, 2017, 19(9):1116-1129

PubMed: 28846096 ( click the link to review the publication )

J Clin Invest, 2017, 127(1):153-168

PubMed: 27893461 ( click the link to review the publication )

J Clin Invest, 2017, 127(2):635-650

PubMed: 28094768 ( click the link to review the publication )

Nat Commun, 2017, 8:16078

PubMed: 28714472 ( click the link to review the publication )

Genes Dev, 2017, 31(17):1754-1769

PubMed: 28982759 ( click the link to review the publication )

Biomaterials, 2017, 144:73-83

PubMed: 28823845 ( click the link to review the publication )

Cancer Res, 2017, 77(9):2512-2521

PubMed: 28202514 ( click the link to review the publication )

Cell Death Differ, 2017, 24(11):1963-1974

PubMed: 28777375 ( click the link to review the publication )

Elife, 2017, 6e22509

PubMed: 28425914 ( click the link to review the publication )

Elife, 2017, 6

PubMed: 29148970 ( click the link to review the publication )

Oncogene, 2017, 36(15):2066-2073

PubMed: 27694901 ( click the link to review the publication )

Cancer Lett, 2017, 411:19-26

PubMed: 28987383 ( click the link to review the publication )

Sci Signal, 2017, 10(499)

PubMed: 28974650 ( click the link to review the publication )

Arch Toxicol, 2017, 91(5):2191-2208

PubMed: 27807597 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(1):102-115

PubMed: 27980105 ( click the link to review the publication )

Eur J Immunol, 2017, 47(6):1009-1021

PubMed: 28493377 ( click the link to review the publication )
Biochem Pharmacol, 2017, 140:41-52

PubMed: 28595877 ( click the link to review the publication )

J Biol Chem, 2017, 292(36):15105-15120

PubMed: 28673964 ( click the link to review the publication )

Analyst, 2017, 142(23):4399-4404

PubMed: 29116264 ( click the link to review the publication )

Mol Cell Biol, 2017, 37(3)e00535-16

PubMed: 27821478 ( click the link to review the publication )

Clin Immunol, 2017, 181:32-42

PubMed: 28579554 ( click the link to review the publication )

Toxicol In Vitro, 2017, 42:38-46

PubMed: 28366708 ( click the link to review the publication )

Mol Cell Biochem, 2017, 429(1-2):91-102

PubMed: 28120212 ( click the link to review the publication )

Arch Oral Biol, 2017, 73:1-6

PubMed: 27632413 ( click the link to review the publication )

Oncol Lett, 2017, 14(1):903-908

PubMed: 28693250 ( click the link to review the publication )

Asia Pac J Clin Oncol, 2017, 13(2):e144-e152

PubMed: 26552712 ( click the link to review the publication )

Oncotarget, 2017, 8(65):108522-108533

PubMed: 29312548 ( click the link to review the publication )

Oncotarget, 2017, 8(63):107206-107222

PubMed: 29291023 ( click the link to review the publication )

J Allergy Clin Immunol, 2017, 140(2):418-430

PubMed: 28043871 ( click the link to review the publication )

Cell Death Dis, 2017, 8(6):e2898

PubMed: 28661475 ( click the link to review the publication )

Oncotarget, 2017, 8(43):74299-74311

PubMed: 29088786 ( click the link to review the publication )

Anat Rec (Hoboken), 2017, 300(2):326-339

PubMed: 27486855 ( click the link to review the publication )

Tumour Biol, 2017, 39(3):1010428317695965

PubMed: 28351336 ( click the link to review the publication )

Thromb Haemost, 2017, 117(2):311-324

PubMed: 27929199 ( click the link to review the publication )

Oncotarget, 2017, 8(29):46801-46817

PubMed: 27086916 ( click the link to review the publication )

Elife, 2017, 6

PubMed: 28692422 ( click the link to review the publication )

Oncotarget, 2017, 8(5):8670-8678

PubMed: 28055968 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(6):E980-E989

PubMed: 28049849 ( click the link to review the publication )

Viruses, 2017, 9(10)

PubMed: 28946654 ( click the link to review the publication )

J Clin Invest, 2016, 126(1):181-94

PubMed: 26619119 ( click the link to review the publication )
Nat Commun, 2016, 7:11190

PubMed: 27048913 ( click the link to review the publication )

Autophagy, 2016, 12(7):1083-93

PubMed: 27172402 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(5):1138-49

PubMed: 26467384 ( click the link to review the publication )

Cancer Res, 2016, 76(6):1313-9

PubMed: 26759243 ( click the link to review the publication )

Br J Pharmacol, 2016, 173(3):471-83

PubMed: 26493374 ( click the link to review the publication )

Cell Death Dis, 2016, 7(8):e2342

PubMed: 27537525 ( click the link to review the publication )

Br J Cancer, 2016, 114(11):1219-26

PubMed: 27140314 ( click the link to review the publication )

Oncogenesis, 2016, 10.1038/oncsis.2016.33

PubMed: 27159675 ( click the link to review the publication )

J Virol, 2016, 90(5):2356-71

PubMed: 26676786 ( click the link to review the publication )

Biochim Biophys Acta, 2016, 1863(4):562-71

PubMed: 26704388 ( click the link to review the publication )

Lab Invest, 2016, 96(10):1128-37

PubMed: 27617402 ( click the link to review the publication )

Am J Cancer Res, 2016, 6(6):1345-57

PubMed: 27429848 ( click the link to review the publication )

Cancer Cell Int, 2016, 16:27

PubMed: 27042160 ( click the link to review the publication )

J Immunother, 2016, 39(3):117-26

PubMed: 26938945 ( click the link to review the publication )

Cell Cycle, 2016, 15(12):1531-7

PubMed: 25483065 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 477(4):607-13

PubMed: 27343560 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 478(1):143-148

PubMed: 27449608 ( click the link to review the publication )

Anticancer Res, 2016, 36(4):1673-82

PubMed: 27069145 ( click the link to review the publication )

Exp Ther Med, 2016, 11(2):669-673

PubMed: 26893664 ( click the link to review the publication )

Oncotarget, 2016, 7(50):83208-83222

PubMed: 27825124 ( click the link to review the publication )

Sci Rep, 2016, 6:21264

PubMed: 26887909 ( click the link to review the publication )

Oncotarget, 2016, 7(3):3520-32

PubMed: 26657288 ( click the link to review the publication )

Tumour Biol, 2016, 37(8):10839-49

PubMed: 26880588 ( click the link to review the publication )

Oncotarget, 2016, 7(51):85492-85501

PubMed: 27863431 ( click the link to review the publication )
Oncotarget, 2016, 7(24):35989-36001

PubMed: 27056884 ( click the link to review the publication )

Oncotarget, 2016, 7(6):6626-38

PubMed: 26675547 ( click the link to review the publication )

Oncotarget, 2016, 7(48):79637-79653

PubMed: 27793034 ( click the link to review the publication )

Oncotarget, 2016, 7(51):84594-84607

PubMed: 27829238 ( click the link to review the publication )

Oncotarget, 2016, 7(47):77815-77824

PubMed: 27780925 ( click the link to review the publication )

Blood, 2015, 24;126(13):1565-74

PubMed: 26254443 ( click the link to review the publication )

Nat Commun, 2015, 6:6891

PubMed: 25922916 ( click the link to review the publication )

Autophagy, 2015, 11(3):452-9

PubMed: 25715028 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(17):3995-4003

PubMed: 26015514 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2015, 112(6):E536-45

PubMed: 25624498 ( click the link to review the publication )

EMBO Rep, 2015, 16(5):618-27

PubMed: 25739811 ( click the link to review the publication )

Cancer Res, 2015, 75(24):5318-28

PubMed: 26670562 ( click the link to review the publication )

Cancer Res, 2015,

PubMed: 25432173 ( click the link to review the publication )

Cell Death Differ, 2015, 10.1038/cdd.2015.8

PubMed: 25698446 ( click the link to review the publication )

J Med Chem, 2015, 58(4):1644-68

PubMed: 25585174 ( click the link to review the publication )

Cell Death Dis, 2015, 6:e1989

PubMed: 26583329 ( click the link to review the publication )

Mol Oncol, 2015, 9(2):409-21

PubMed: 25308513 ( click the link to review the publication )

Mol Oncol, 2015, 9(2):409-21

PubMed: ( click the link to review the publication )

J Biol Chem, 2015, 290(19):12290-9

PubMed: 25829495 ( click the link to review the publication )

J Biol Chem, 2015, 290(34):20841-55

PubMed: 26124276 ( click the link to review the publication )

Cancer Cell Int, 2015, 15:34

PubMed: 25852302 ( click the link to review the publication )

Neurogastroenterol Motil, 2015, 10.1111/nmo.12521

PubMed: 25690069 ( click the link to review the publication )

Int J Oncol, 2015, 46(2):667-76

PubMed: 25434832 ( click the link to review the publication )

Eur J Pharm Sci, 2015, 70:64-71

PubMed: ( click the link to review the publication )
Eur J Pharm Sci, 2015, 70:64-71

PubMed: 25596561 ( click the link to review the publication )

Exp Cell Res, 2015, 335(1):62-7

PubMed: 26024774 ( click the link to review the publication )

Exp Cell Res, 2015, 10.1016/j.yexcr.2015.04.016

PubMed: 25936772 ( click the link to review the publication )

BMC Cancer, 2015, 15:919

PubMed: 26585594 ( click the link to review the publication )

Chembiochem, 2015, 16(5):757-65

PubMed: 25711460 ( click the link to review the publication )

PLoS One, 2015, 10(11):e0143685

PubMed: 26606677 ( click the link to review the publication )

Biochem Biophys Res Commun, 2015, 464(1):286-91

PubMed: 26116776 ( click the link to review the publication )

Exp Hematol, 2015, 43(3):180-190.e6

PubMed: 25461257 ( click the link to review the publication )

Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, 2015, 10.1016/j.mrfmmm.2015.04.005

PubMed: ( click the link to review the publication )

Cell Biochem Funct, 2015, 33(5):334-40

PubMed: 26178811 ( click the link to review the publication )

Anticancer Res, 2015, 35(3):1803-8

PubMed: 25750346 ( click the link to review the publication )

Anticancer Res, 2015,

PubMed: 26637878 ( click the link to review the publication )

Oncotarget, 2015, 6(26):22624-40

PubMed: 26265439 ( click the link to review the publication )

Oncotarget, 2015, 6(34):36338-53

PubMed: 26462148 ( click the link to review the publication )

Oncotarget, 2015, 6(8):5582-96

PubMed: 25714024 ( click the link to review the publication )

Arch Pharm Chem Life Sci, 2015, 348: 1-11

PubMed: 25641608 ( click the link to review the publication )

Oncotarget, 2015, 6(1):409-26

PubMed: 25565667 ( click the link to review the publication )

Oncotarget, 2015, 6(34):35667-83

PubMed: 26447615 ( click the link to review the publication )

Oncotarget, 2015, 6(14):12405-20

PubMed: 25915159 ( click the link to review the publication )

Hepatol Res, 2015, 45(9):1023-1033

PubMed: 25297967 ( click the link to review the publication )

Nat Commun, 2014, 5:5637

PubMed: 25472497 ( click the link to review the publication )

Autophagy, 2014, 10(10):1776-86

PubMed: 25126729 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(21):5446-55

PubMed: 25208882 ( click the link to review the publication )

Leukemia, 2014, 28(10):1960-8

PubMed: 24577530 ( click the link to review the publication )
Chem Sci, 2014, 5, 2794–2803

PubMed: ( click the link to review the publication )

Biomaterials, 2014, 16(2):R41

PubMed: 24745479 ( click the link to review the publication )

Cell Death Differ, 2014, 21(7):1170-7

PubMed: 24682005 ( click the link to review the publication )

Cell Death Differ, 2014, 10.1038/cdd.2014.158

PubMed: 25301069 ( click the link to review the publication )

Cancer Lett, 2014, 10.1016/j.canlet.2014.09.024

PubMed: 25304383 ( click the link to review the publication )

Cancer Lett, 2014, 348(1-2):38-49

PubMed: 24650799 ( click the link to review the publication )

Sci Signal, 2014, 7(357):ra122

PubMed: 25538080 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1514

PubMed: 25375379 ( click the link to review the publication )

Biomaterials Science, 2014, 10.1039/C4BM00072B

PubMed: ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1445

PubMed: 25299770 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1291

PubMed: 24922075 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1275

PubMed: 24901046 ( click the link to review the publication )

Acta Neuropathol Commun, 2014, 10.1186/2051-5960-2-57

PubMed: 24887326 ( click the link to review the publication )

Mol Cancer Ther, 2014, 10.1158/1535-7163.MCT-13-0998

PubMed: 24739394 ( click the link to review the publication )

Mol Cancer Res, 2014, 13(12):3332-42

PubMed: 25154561 ( click the link to review the publication )

Mol Cancer Res, 2014, (4):550-9

PubMed: 24469836 ( click the link to review the publication )

J Immunol, 2014, 193(10):4914-23

PubMed: 25288570 ( click the link to review the publication )

Bone, 2014, 67:166-74

PubMed: 25016096 ( click the link to review the publication )

J Biol Chem, 2014, 289(22):15495-15506

PubMed: 24739390 ( click the link to review the publication )

J Immunother, 2014, 37(1):8-15

PubMed: 24316551 ( click the link to review the publication )

Int J Mol Sci, 2014, 15(11):20500-17

PubMed: 25387078 ( click the link to review the publication )

Int J Cardiol, 2014, 176(3):923-9

PubMed: 25194861 ( click the link to review the publication )

Int J Hyperthermia, 2014, 30(7):502-12

PubMed: 25354679 ( click the link to review the publication )

Cell Cycle, 2014, 10.4161/15384101.2014.973321

PubMed: ( click the link to review the publication )
Thromb Res, 2014, 134(6):1311-5

PubMed: 25288466 ( click the link to review the publication )

Thromb Res, 2014, 133(1):73-9

PubMed: 24268298 ( click the link to review the publication )

PLoS One, 2014, 9(9):e103015

PubMed: 25181509 ( click the link to review the publication )

PLoS One, 2014, 9(1):e84388

PubMed: 24427286 ( click the link to review the publication )

PLoS One, 2014, 9(9):e106571

PubMed: 25192188 ( click the link to review the publication )

PLoS One, 2014, 9(2):e88587

PubMed: 24523919 ( click the link to review the publication )

PLoS One, 2014, 9(8):e105049

PubMed: 25126950 ( click the link to review the publication )

PLoS One, 2014, 9(3):e91782

PubMed: 24626299 ( click the link to review the publication )

PLoS One, 2014, 9(5):e96733

PubMed: 24824755 ( click the link to review the publication )

Leuk Lymphoma, 2014, 5:1-12

PubMed: 25373508 ( click the link to review the publication )

Biomed Res Int, 2014, 2014:306718

PubMed: ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2013, 110(11):4321-6

PubMed: 23447565 ( click the link to review the publication )

Cell Death Differ, 2013, 20(11):1532-45

PubMed: 23933817 ( click the link to review the publication )

Mol Cancer, 2013, 12(1):42

PubMed: 23680104 ( click the link to review the publication )

Int J Cancer, 2013, 133(8):1813-24

PubMed: 23580240 ( click the link to review the publication )

J Neurosci, 2013, 33(46):18098-108

PubMed: 24227720 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e702

PubMed: 23828565 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e931

PubMed: 24263105 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e762

PubMed: 23928701 ( click the link to review the publication )

Br J Cancer, 2013, 108(9):1870-8

PubMed: 23558901 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e690

PubMed: 23807219 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e801

PubMed: 24030153 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e742

PubMed: 23887633 ( click the link to review the publication )

Br J Haematol, 2013, 163(3):377-84

PubMed: 24033315 ( click the link to review the publication )
Br J Haematol, 2013, 161(2):245-54

PubMed: 23398569 ( click the link to review the publication )

Stem Cells Transl Med, 2013, 2(9):690-702

PubMed: 23934910 ( click the link to review the publication )

Cancer Sci, 2013, 104(6):732-9

PubMed: 23421409 ( click the link to review the publication )

Mol Cancer Res, 2013, 11(2):109-21

PubMed: 23233484 ( click the link to review the publication )

Cancer Gene Ther, 2013, 20(7):386-93

PubMed: 23788110 ( click the link to review the publication )

J Biol Chem, 2013, 288(10):6826-34

PubMed: 23329846 ( click the link to review the publication )

Apoptosis, 2013, 18(11):1403-15

PubMed: 23760752 ( click the link to review the publication )

Biomed Pharmacother, 2013, 67(7):583-91

PubMed: 23706691 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2013, 274(2):319-27

PubMed: 24321340 ( click the link to review the publication )

Int J Biochem Cell Biol, 2013, 45(5):944-51

PubMed: 23395630 ( click the link to review the publication )

PLoS One, 2013, 8(5):e63232

PubMed: 23658815 ( click the link to review the publication )

PLoS One, 2013, 8(11):e78570

PubMed: 24223823 ( click the link to review the publication )

Biochem Biophys Res Commun, 2013, 437(4):565-72

PubMed: 23850692 ( click the link to review the publication )

Leuk Lymphoma, 2013, 54(2):372-80

PubMed: 22830613 ( click the link to review the publication )

Exp Dermatol, 2013, 22(8):518-23

PubMed: 23802633 ( click the link to review the publication )

Basic Clin Pharmacol Toxicol, 2013, 113(3):145-51

PubMed: 23557083 ( click the link to review the publication )

J Ovarian Res, 2013, 6(1):72

PubMed: 24103422 ( click the link to review the publication )

Phys Biol, 2013, 10(3):035002

PubMed: 23735516 ( click the link to review the publication )

Cytometry A, 2013, 83(2):227-34

PubMed: 23165976 ( click the link to review the publication )

Oncotarget, 2013,

PubMed: 24334291 ( click the link to review the publication )

Blood, 2012, 120(19):3978-85

PubMed: 22927247 ( click the link to review the publication )

Mol Cell, 2012, 46(5):573-83

PubMed: 22560721 ( click the link to review the publication )

J Clin Invest, 2012, 122(6):2018-31

PubMed: 22622039 ( click the link to review the publication )

EMBO J, 2012, 31(10):2322-35

PubMed: 22510886 ( click the link to review the publication )
Oncogene, 2012, 31(26):3177-89

PubMed: 22056880 ( click the link to review the publication )

Breast Cancer Res, 2012, 14(3):R96

PubMed: 22703841 ( click the link to review the publication )

Anal Chem, 2012, 84(11):4703-10

PubMed: 22533353 ( click the link to review the publication )

Br J Haematol, 2012, 159(5):565-71

PubMed: 23025479 ( click the link to review the publication )

Mol Cancer Res, 2012, 10(3):347-59

PubMed: 22241218 ( click the link to review the publication )

J Biol Chem, 2012, 287(25):21357-70

PubMed: 22553204 ( click the link to review the publication )

J Biol Chem, 2012, 287(21):17682-92

PubMed: 22433870 ( click the link to review the publication )

Mol Endocrinol, 2012, 26(9):1508-20

PubMed: 22771494 ( click the link to review the publication )

Phytother Res, 2012, 27(6):835-40

PubMed: 22899281 ( click the link to review the publication )

BMC Cancer, 2012, 12:541

PubMed: 23171055 ( click the link to review the publication )

PLoS One, 2012, 7(8):e43158

PubMed: 22912816 ( click the link to review the publication )

PLoS One, 2012, 7(12):e52333

PubMed: 23284992 ( click the link to review the publication )

J Pharmacol Sci, 2012, 119(4):330-40

PubMed: 22814102 ( click the link to review the publication )

Blood, 2011, 117(26):7145-54

PubMed: 21562047 ( click the link to review the publication )

J Clin Invest, 2011, 121(3):1053-63

PubMed: 21317538 ( click the link to review the publication )

Leukemia, 2011, 25(11):1728-38

PubMed: 21701487 ( click the link to review the publication )

Neuro Oncol, 2011, 13(12):1265-76

PubMed: 21880625 ( click the link to review the publication )

Cancer Res, 2011, 71(13):4494-505

PubMed: 21555370 ( click the link to review the publication )

Oncogene, 2011, 30(37):3918-29

PubMed: 21460857 ( click the link to review the publication )

Am J Nephrol, 2011, 34(6):549-59

PubMed: 22123611 ( click the link to review the publication )

Cancer Chemoth Pharm, 2011, 67(3):557-67

PubMed: 20473610 ( click the link to review the publication )

PLoS One, 2011, 6(6):e20423

PubMed: 21674052 ( click the link to review the publication )

PLoS One, 2011, 6(9):e24102

PubMed: 21949692 ( click the link to review the publication )

Biochem Biophys Res Commun, 2011, 408(2):344-9

PubMed: 21514278 ( click the link to review the publication )
Curr Pharmacogenomics Person Med, 2011, 9(3):184-190

PubMed: 22162984 ( click the link to review the publication )

Mol Cancer Ther, 2010, 19(20):5591-601

PubMed: 20587662 ( click the link to review the publication )

J Biol Chem, 2010, 285(26):19910-20

PubMed: 20421300 ( click the link to review the publication )

Apoptosis, 2010, 15(10):1256-69

PubMed: 20582477 ( click the link to review the publication )

Exp Hematol, 2010, 38(10):908-921

PubMed: 20540984 ( click the link to review the publication )

产品安全说明书

Bcl-2抑制剂选择性比较

生物活性

产品描述

特性

ABT-737是第一代抗凋亡BCL-2家族蛋白小分子抑制剂。

靶点

Bcl-2 ^[1] (Cell-free assay)	Bcl-xL ^[1] (Cell-free assay)	Bcl-w ^[1] (Cell-free assay)	Bcl-B ^[1] (Cell-free assay)
30.3 nM(EC50)	78.7 nM(EC50)	197.8 nM(EC50)	1.82 μM(EC50)

体外研究

ABT-737降低BCL-2/BAX异质二聚体,而诱导HL60细胞凋亡,但是对细胞周期分布没有抑制效果。ABT-737也诱导细胞色素C从线粒体中释放，促进BAX构象改变，BAX与凋亡相关。在白血病模型中，ABT-737按30 mg/kg处理，阻断53%白血病负荷，且使鼠寿命明显延长。ABT-737不会导致血细胞数和血清组成发生异常。^[1]通过使Mcl-1失活而使抵抗细胞（Hela和MCF-7）对ABT-737敏感。当Mcl-1无效时，ABT-737也导致BAX/BAK-依赖的细胞色素C释放。ABT-737延长携带BCL-2肿瘤的鼠寿命。^[2]ABT-737从BCL2’s BH3结合袋取代BIM,使BIM激活BAX,诱导线粒体透化作用,快速致死慢性淋巴细胞性白血病(CLL)细胞。^[3] Noxa正向调节增强H196细胞对ABT-737敏感性。ABT-737抑制多种SCLC细胞系，包括NCI-H889, NCI-H1963, NCI-H1417, NCI-H146等的增殖，并诱导细胞凋亡。最近研究显示，ABT-737作用于ATLL细胞，明显诱导HTLV-1感染的T细胞凋亡。ABT-737按100 mg/kg剂量作用于ATLL鼠模型显示出强抗癌活性。^[5]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
OCI-Ly1	NWH6TI5jS2WubDDWbYFjcWyrdImgRZN{[Xl?	NWPqUVRyOjVyIH7NxsA>	MWS3NkBp	MkThSG1UVw>?	M2nybYNifXOnZDC5O{UhdG:\|czDv[kB3cWGkaXzpeJkhcW5iY3XscJMhfHKjboPm[YN1\WRid3n0bEBDS0x4IIPpVm5C	MkW2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ4NUeyPFgoRjJ4NkW3Nlg5RC:jPh?=
KG1a	M3jPSWNmdGxiVnnhZoltcXS7IFHzd4F6	MkHWNE0yOCEQvF2=	M2f0NVI1KGh?	MXvEUXNQ	NWr3[XlGUUN3ME23MlY5KM7:TTyg[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	M{O2[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NUWyO\|EzLz5{NkW1NlcyOjxxYU6=
Kasumi-1	NHvJdZFE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	M13Cc\|AuOTBizszN	Mn3INlQhcA>?	NGi2bYtFVVOR	NGe4PFJKSzVyPUSuPFch\|ryPLDDk[YNz\WG\|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	NF7UZXU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkW1NlcyOid-Mk[1OVI4OTJ:L3G+
KG1a	M{OyZWFxd3C2b4Ppd{BCe3OjeR?=	MVewMVExKM7:TR?=	M3\RVVI1KGh?	MV\EUXNQ	NYPWdXZpcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjV3MkexNkc,OjZ3NUK3NVI9N2F-
Kasumi-1	MlHhRZBweHSxc3nzJGF{e2G7	M1T6UFAuOTBizszN	NWXicWZUOjRiaB?=	MknDSG1UVw>?	Mm\rbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	NIXqUFE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkW1NlcyOid-Mk[1OVI4OTJ:L3G+
MC-3	Mo\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUW1M\|ExNzJyIN88US=>	M4nZRlI1KGh?	MYDEUXNQ	MWDpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	M1LX[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NES3OlE2Lz5{NkS0O\|YyPTxxYU6=
HN22	NGLvWlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXqyMlUwPy53L{KyMlUh\|ryP	NUnqXnhoOjRiaB?=	MmLNSG1UVw>?	M1PRNolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjR2N{[xOUc,OjZ2NEe2NVU9N2F-
MC-3	Mn3PRZBweHSxc3nzJGF{e2G7	NVzOXW9lPS9zMD:yNEDPxE1?	NGrMbJAzPCCq	NX:5OVU{TE2VTx?=	M3O5Solv\HWlZYOgZ4F{eGG\|ZT3t[YRq[XSnZDDhdI9xfG:\|aYO=	NUTEO4wxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[0OFc3OTVpPkK2OFQ4PjF3PD;hQi=>
HN22	MkXvRZBweHSxc3nzJGF{e2G7	MYSyMlUwPy53L{KyMlUh\|ryP	Ml;TNlQhcA>?	M2\TSWROW09?	Ml7ibY5lfWOnczDjZZNx[XOnLX3l[IlifGWmIHHwc5B1d3Orcx?=	M16xXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NES3OlE2Lz5{NkS0O\|YyPTxxYU6=
MOLT-4	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUOxNE02ODByIH7N	NY[zZ4x3PzJiaB?=	NGPnTJlFVVOR	MlW3TWM2OD1yLkG5PEDPxE1?	MkDvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ\|OUKzN\|IoRjJ4M{myN\|MzRC:jPh?=
RS4;11	M3niZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGnyW5AyOC13MECwJI5O	MYe3NkBp	NHPuNpJFVVOR	MWTJR\|UxRTBwMECyJO69VQ>?	NFfufXY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkO5NlM{Oid-Mk[zPVI{OzJ:L3G+
JURKAT	M3ryeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUmxNE02ODByIH7N	NF7tWVY4OiCq	M4WxdmROW09?	MYnJR\|UxRTZ4IN88US=>	NVPtdYZSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[zPVI{OzJpPkK2N\|kzOzN{PD;hQi=>
CEM R	M3XMdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUGxNE02ODByIH7N	NHG2c\|A4OiCq	Mlu2SG1UVw>?	M1q0TmlEPTB;NT60JO69VQ>?	MmXGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ\|OUKzN\|IoRjJ4M{myN\|MzRC:jPh?=
CEM S	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFHnRZQyOC13MECwJI5O	NWTvR5pkPzJiaB?=	NFyxRpBFVVOR	NFfy[JZKSzVyPUGyMlEh\|ryP	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjN7MkOzNkc,OjZ\|OUKzN\|I9N2F-
MOLT-4	NXLPV3d2SXCxcITvd4l{KEG\|c3H5	NHi1[2QyOC1zMECwJI5O	MnzFNlQhcA>?	M3\DXGROW09?	MUfjZZV{\XNidHjlJINt\WG4YXflJI9nKEKlbD2yJIFv\CC2aHWg[I94dnKnZ4XsZZRqd25ib3[gRoNtNXiOIHHu[EBO[2xvMR?=	NXO1dVJWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[zPVI{OzJpPkK2N\|kzOzN{PD;hQi=>
CEM S	M1TUeGFxd3C2b4Ppd{BCe3OjeR?=	Mkn5NVAuOTByMDDuUS=>	Ml3CNlQhcA>?	Ml3nSG1UVw>?	NIrsfYtk[XW\|ZYOgeIhmKGOuZXH2ZYdmKG:oIFLjcE0zKGGwZDD0bIUh\G:5boLl[5Vt[XSrb36gc4YhSmOuLYjMJIFv\CCPY3ytNS=>	NV\ROpp4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[zPVI{OzJpPkK2N\|kzOzN{PD;hQi=>
JURKAT	NEHCUJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEThfG0yODBvMUCwNEBvVQ>?	NWfI[VVQPDhiaB?=	MnnySG1UVw>?	NVjUSVE6UUN3ME25OVXDuTlwMzDuUS=>	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF5MkK2PUc,OjZzN{KyOlk9N2F-
LOUCY	M3;PXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mon4NVAxNTFyMECgcm0>	M2HOV\|Q5KGh?	MUDEUXNQ	NGnjc4lKSzVyPUOyMljDuTFyLkmgcm0>	NFPVWpk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkG3NlI3QSd-Mk[xO\|IzPjl:L3G+
WM-115	MmjxR4VtdCCYaXHibYxqfHliQYPzZZk>	NFHzZXoyODEEoH7N	M2fYe\|czKGh?		M{n6cYVvcGGwY3XzJIN2emO3bXnuMYlv\HWlZXSgZY51cS2\|dYL2bZZidMLi	NUS5SIpoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xNVY4PzZpPkK2NVE3Pzd4PD;hQi=>
B16	M1TpXWNmdGxiVnnhZoltcXS7IFHzd4F6	M2fo[lExOMLibl2=	MUG3NkBp		M3\Vb4VvcGGwY3XzJIN2emO3bXnuMYlv\HWlZXSgZY51cS2\|dYL2bZZidMLi	M{PpO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUG2O\|c3Lz5{NkGxOlc4PjxxYU6=
HL-60	M3\3c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MVi3NkBp		M1LIS2lEPTEEoE2gNVAvPyCwTR?=	NH6wV5A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkC0OVYxQSd-Mk[wOFU3ODl:L3G+
MOLM-13	MoXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MWe3NkBp		MoLCTWM2OMLiPTCyO{46KG6P	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB2NU[wPUc,OjZyNEW2NFk9N2F-
OCI-AML3	M1LTZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MmX3O\|IhcA>?		NWLSN29DUUN3MNMgQUAyQTVyIH7N	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB2NU[wPUc,OjZyNEW2NFk9N2F-
BCWM.1	MmTRRZBweHSxc3nzJGF{e2G7	M3XucVAuOS54IN88US=>	M4XhWVI1KGh?		MV3pcoR2[2W\|IHPlcIwh[XCxcITvd4l{	NEXnZ5c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUi5N\|I6OCd-MkW4PVMzQTB:L3G+
MWCL-1	NIO4cIVCeG:ydH;zbZMhSXO\|YYm=	NXPhU457OC1zLk[g{txO	NWL4SXpROjRiaB?=		NWLzc\|JZcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?=	NF\ZWYw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUi5N\|I6OCd-MkW4PVMzQTB:L3G+
MM.1s	MV7BdI9xfG:\|aYOgRZN{[Xl?	MoK5NE0yNjZizszN	NHTvWmEzPCCq		NH3pU\|NqdmS3Y3XzJINmdGxiYYDvdJRwe2m\|	MofKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6OUOyPVAoRjJ3OEmzNlkxRC:jPh?=
HCT116	MknUSpVv[3Srb36gRZN{[Xl?	MXSzM\|ExKM7:TR?=	NW\Ob5hzOTMEoHlCpC=>	MVTEUXNQ	MYTpcoR2[2W\|IHGg[I9{\S2mZYDlcoRmdnRiaX7jdoVie2ViaX6gUGM{Si2LSTDjc453\XK\|aX;uJIFv\CCVUWPUUVEh\GWpcnHkZZRqd25?	Ml7xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5MUWwNlgoRjJ3N{G1NFI5RC:jPh?=
HCT116 BAX BAK1 DKO	MUTGeY5kfGmxbjDBd5NigQ>?	NXj1d2lKOy9zMDFOwG0>	NWfscWVqOTMEoHlCpC=>	NIjwTmdFVVOR	MUTpcoR2[2W\|IHGg[I9{\S2mZYDlcoRmdnRiaX7jdoVie2ViaX6gUGM{Si2LSTDjc453\XK\|aX;uJIFv\CCVUWPUUVEh\GWpcnHkZZRqd25?	NI\aZlk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUexOVAzQCd-MkW3NVUxOjh:L3G+
HCT116	NFrVWWNHfW6ldHnvckBCe3OjeR?=	NVLmdmhVOTBizszN	NYHWdnd6OTMEoHlCpC=>	NFL1UIdFVVOR	MXfpcoNz\WG\|ZYOgS2ZRNUyFM1KgdJVv[3Sj	M4K4[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{G1NFI5Lz5{NUexOVAzQDxxYU6=
HCT116 BAX BAK1 DKO	NEXac2FHfW6ldHnvckBCe3OjeR?=	NWr4do5KOTBizszN	MUGxNuKhcMLi	MV;EUXNQ	MkHPbY5kemWjc3XzJGdHWC2OQ{PCJJB2dmO2YR?=	NYnaSFFoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3NVUxOjhpPkK1O\|E2ODJ6PD;hQi=>
HCT116	MWHBeZRweGijZ4mgRZN{[Xl?	MnnMNVAh\|ryP	MUSxNuKhcMLi	MoL2SG1UVw>?	MkjnbY5lfWOnczDhJINwdXCuZYTlJIF2fG:yaHHnbYMhemW\|cH;ud4U>	Mn:wQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5MUWwNlgoRjJ3N{G1NFI5RC:jPh?=
HCT116 BAX BAK1 DKO	NU\NUmZGSXW2b4DoZYd6KEG\|c3H5	MY[xNEDPxE1?	MU[xNuKhcMLi	MVLEUXNQ	MX3pcoR2[2W\|IHGgZ49ueGyndHWgZZV1d3CqYXfpZ{Bz\XOyb37z[S=>	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTdzNUCyPEc,OjV5MUWwNlg9N2F-
U937	M1P6RWFxd3C2b4Ppd{BCe3OjeR?=	NHqxTYQxNjF{NT2yJO69VQ>?	NUHK[Io4OjRiaB?=		NFfvRpZmdmijbnPld{BFUEFxWD2xNU1qdmS3Y3XkJIFxd3C2b4Ppdy=>	MnviQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5MUSwNlQoRjJ3N{G0NFI1RC:jPh?=
U937	NHLUVHZCeG:ydH;zbZMhSXO\|YYm=	NEfocpcxNjVizszN	Mmr6NlQhcA>?		Mni3[Y5p[W6lZYOgZ4xm[X[jZ3Wgc4YhWEGUUDDhcoQh[2G\|cHHz[U0{KGG\|IIflcIwh[XNiTn;4ZUBt\X[nbB?=	NVjWfoRLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3NVQxOjRpPkK1O\|E1ODJ2PD;hQi=>
HL-60 AAA-Bcl-2	MUDBdI9xfG:\|aYOgRZN{[Xl?	M2TuO\|AuPSEQvF2=	MnvIOFghcA>?		M4LGZ2lEPTB;MD64O{DPxG4xvJzpcoR2[2W\|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	MnzhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5MUG0OlAoRjJ3N{GxOFYxRC:jPh?=
HL-60 EEE-Bcl-2	NEPoZYxCeG:ydH;zbZMhSXO\|YYm=	NE\ZUFIxNTVizszN	MXu0PEBp		NH30Zm9KSzVyPUWg{txu97zOIHnu[JVk\XNiY3XscEBieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	NWfueWw3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3NVE1PjBpPkK1O\|EyPDZyPD;hQi=>
U87	MnjkSpVv[3Srb36gRZN{[Xl?	M4\ZdlUxKM7:TR?=	MXyyOEBp		Mnf0doVlfWOnczD0bIUhdVKQQTDlfJBz\XO\|aX;uJIxmfmWuczDv[kBOVVBvMjygUW1RNTF2IHHu[EBD[2xvMh?=	NVnCVJYzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2Olc3PjNpPkK1OlY4PjZ\|PD;hQi=>
K562	MYXD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	M1znN\|EuOTBizszN	NHvFeXE1QCCq	NGPPfmtFVVOR	NFjy[Y9KSzVyPUK2Mlch\|ryP	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV7NkW2NUc,OjV3OU[1OlE9N2F-
K562/Mcl -1-IRESBim	Ml\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUfJR\|UxRTlwMzFOwG0>	NFixfJk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUWzOVkxOCd-MkW1N\|U6ODB:L3G+
K562/Bcl- 2-IRESBim	NGL2eWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mki0TWM2OD1yLkO1JO69VQ>?	NXv5emdLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1N\|U6ODBpPkK1OVM2QTByPD;hQi=>
Jurkat	MnfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVntcG5sUUN3ME2wMlY3KM7:TR?=	M{LibVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUO1PVAxLz5{NUWzOVkxODxxYU6=
JurkatΔBak	M{fkR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn;qTWM2OD53MDFOwG0>	NF;nfZc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUWzOVkxOCd-MkW1N\|U6ODB:L3G+
HL60/VCR	NEK1WWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVrIXIlNUUN3ME6xNFAh\|ryP	MmHHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3M{W5NFAoRjJ3NUO1PVAxRC:jPh?=
Kasumi-1	M2f2Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3;1c2lEPTB;MD6wNUDPxE1?	NED1PHI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUWzOVkxOCd-MkW1N\|U6ODB:L3G+
Kasumi-1/ABT	M2i1SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX3JR\|UxRTBwNUGg{txO	Mn:4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3M{W5NFAoRjJ3NUO1PVAxRC:jPh?=
THP-1	NE\kdYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXfJR\|UxRTFwMkeg{txO	NFrsdWY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUWzOVkxOCd-MkW1N\|U6ODB:L3G+
U937	M4n3Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXLJR\|UxRTVwMkmg{txO	Mm\SQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3M{W5NFAoRjJ3NUO1PVAxRC:jPh?=
C1498	M{nSXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYPldpZGUUN3ME22MlE{KM7:TR?=	NWf0TIl{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1N\|U6ODBpPkK1OVM2QTByPD;hQi=>
RPMI 8226	MkW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mon0TWM2OD1yLkK1JO69VQ>?	NEPXWYk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUWzOVkxOCd-MkW1N\|U6ODB:L3G+
MM.1S	M3PaV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVXJR\|UxRTBwNECg{txO	NX;TWJlERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1N\|U6ODBpPkK1OVM2QTByPD;hQi=>
NCI-H929	NEfnd4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVjJR\|UxRTF3LkKxJO69VQ>?	NH;ScW49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUWzOVkxOCd-MkW1N\|U6ODB:L3G+
U266	NFjVTmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUW0PYppUUN3ME2wMlY5KM7:TR?=	NEmzZ2E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUWzOVkxOCd-MkW1N\|U6ODB:L3G+
MCF-7	M4TQSGNmdGxiVnnhZoltcXS7IFHzd4F6	NVW0Woc3PSEQvF2=	M3K4NlQ5KGh?	NUSzbIRyTE2VTx?=	MV7lcohidmOnczD0bIUhe2Wwc3n0bZZqfHlidH:gc5IhemGmaXH0bY9v	NUi2R5p1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0NFkyOjRpPkK1OFA6OTJ2PD;hQi=>
MCF-7	NHXHelZCeG:ydH;zbZMhSXO\|YYm=	NXHpVW14PSEQvF2=	M4\LflQwOjRxNEigbC=>	Mne4SG1UVw>?	M2n4bYlv[3KnYYPld{B1cGViY3zlZZZm\CCSQWLQ	M1OzelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEC5NVI1Lz5{NUSwPVEzPDxxYU6=
MCF-7	NUfBT5lKTnWwY4Tpc44hSXO\|YYm=	MlLtOUDPxE1?	NVOyO4R[OjRiaB?=	MUfEUXNQ	M2XldoVvcGGwY3XzJJRp\WyndnXsJI9nKE2lbD2xJIV5eHKnc4Ppc47DqA>?	Ml\CQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2MEmxNlQoRjJ3NEC5NVI1RC:jPh?=
MDA-MB 231	Moi5SpVv[3Srb36gRZN{[Xl?	NYLHdJZFPSEQvF2=	MlzYNlQhcA>?	NHnv[oFFVVOR	M1jUUYVvcGGwY3XzJJRp\WyndnXsJI9nKE2lbD2xJIV5eHKnc4Ppc47DqA>?	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTRyOUGyOEc,OjV2MEmxNlQ9N2F-
ZR-75-1	NUPEd5JZTnWwY4Tpc44hSXO\|YYm=	NVnQUINOPSEQvF2=	M{G4XlI1KGh?	M17SOGROW09?	NIrQWZZmdmijbnPld{B1cGWuZY\lcEBw\iCPY3ytNUBmgHC{ZYPzbY9vyqB?	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTRyOUGyOEc,OjV2MEmxNlQ9N2F-
A549	NHzLZlFE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	MX2wMVIxKM7:TR?=	NXq3eZRHPzJiaB?=	NVrzWVBTTE2VTx?=	Mmqz[IVkemWjc3XzJJRp\SClZXzsJJN2en[rdnHsJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyJINwdWKrbnXkJJdqfGhiYYPwbZJqdg>?	NU\MUFRoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzPFg4PjJpPkK1N\|g5PzZ{PD;hQi=>
H1299	NGOwc2dE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	M{j3XVAuOjBizszN	NX3yR4JNPzJiaB?=	MonISG1UVw>?	Mlm4[IVkemWjc3XzJJRp\SClZXzsJJN2en[rdnHsJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyJINwdWKrbnXkJJdqfGhiYYPwbZJqdg>?	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTN6OEe2Nkc,OjV\|OEi3OlI9N2F-
HO-8910	M{noZmNmdGxiVnnhZoltcXS7IFHzd4F6	M2XJblAuOjBizszN	M2TqNFczKGh?	M4PERmROW09?	NEXBZ3pl\WO{ZXHz[ZMhfGinIHPlcIwhe3W{dnn2ZYwhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZIh[2:vYnnu[YQhf2m2aDDhd5Bqemmw	NE\5TYM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUO4PFc3Oid-MkWzPFg4PjJ:L3G+
HT-29	M2nUfGNmdGxiVnnhZoltcXS7IFHzd4F6	Mn\FNE0zOCEQvF2=	NWjQXnY2PzJiaB?=	MVHEUXNQ	M1zSbYRm[3KnYYPld{B1cGViY3XscEB{fXK4aY\hcEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldkBkd22kaX7l[EB4cXSqIHHzdIlzcW5?	M2noeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{i4O\|YzLz5{NUO4PFc3OjxxYU6=
HCT-116	NYrrNnNtS2WubDDWbYFjcWyrdImgRZN{[Xl?	NGjZcFMxNTJyIN88US=>	M3LFVVczKGh?	NETVUHNFVVOR	M33MWYRm[3KnYYPld{B1cGViY3XscEB{fXK4aY\hcEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldkBkd22kaX7l[EB4cXSqIHHzdIlzcW5?	M1TBbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{i4O\|YzLz5{NUO4PFc3OjxxYU6=
A549	M4LkW2Fxd3C2b4Ppd{BCe3OjeR?=	MoKxNlAh\|ryP	NF3kc\|Y1QCCq	NHfrfppFVVOR	NVToOYRxcW6mdXPld{BieG:ydH;zbZMhe2mpbnnmbYNidnSueTDjc41jcW6nZDD3bZRpKGG\|cHnybY4>	M3n2PVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{i4O\|YzLz5{NUO4PFc3OjxxYU6=
H1299	NWP0T291SXCxcITvd4l{KEG\|c3H5	MYOyNEDPxE1?	NX7STFhVPDhiaB?=	NFW3WXVFVVOR	M4LvNYlv\HWlZYOgZZBweHSxc3nzJJNq\26rZnnjZY51dHliY3;tZolv\WRid3n0bEBie3Crcnnu	M{\1cFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{i4O\|YzLz5{NUO4PFc3OjxxYU6=
Sc-1	NEnwe21E\WyuIG\pZYJqdGm2eTDBd5NigQ>?	MonHNE4xODBzLUGg{txO	NIn6Uo46PiCq		NWjM[\|g4\GWlcnXhd4V{KHSqZTDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	M2GycFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{ezOVA5Lz5{NUO3N\|UxQDxxYU6=
OcI-LY18	MnzNR4VtdCCYaXHibYxqfHliQYPzZZk>	MoXUNE4xODBzLUGg{txO	NULHVXY{QTZiaB?=		MXrk[YNz\WG\|ZYOgeIhmKGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	NGT3O3M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUO3N\|UxQCd-MkWzO\|M2ODh:L3G+
RL	M1;xbWNmdGxiVnnhZoltcXS7IFHzd4F6	MorPNE4xODBzLUGg{txO	M4DndFk3KGh?		Mlnz[IVkemWjc3XzJJRp\SClZXzsJJZq[WKrbHn0fUBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	MojqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV\|N{O1NFgoRjJ3M{ezOVA5RC:jPh?=
RKO	NYjjTZpPS2WubDDWbYFjcWyrdImgRZN{[Xl?	NYTtPIVOOC1zMDFOwG0>	NH\BZXozPOLCiXlCpC=>	M3PGXmROW09?	M3rFT2lEPTB-4pEJNlXjiIoEtV2=	MmXjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV\|MESzPFMoRjJ3M{C0N\|g{RC:jPh?=
Caco-2	M3fVR2NmdGxiVnnhZoltcXS7IFHzd4F6	M{C3dFAuOTBizszN	MnyyNlTjiImqwrC=	M164O2ROW09?	MXnJR\|UxRTF7LkhihKnDvU1?	MmKwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV\|MESzPFMoRjJ3M{C0N\|g{RC:jPh?=
DLD1	M1v0PWNmdGxiVnnhZoltcXS7IFHzd4F6	M4PwdVAuOTBizszN	M3i2TlI16oDLaNMg	MUDEUXNQ	Mmq3TWM2OD1zOD63PQKBkcL3TR?=	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTNyNEO4N{c,OjV\|MESzPFM9N2F-
LS411N	M1;jfGNmdGxiVnnhZoltcXS7IFHzd4F6	NIfMWmQxNTFyIN88US=>	MVeyOQKBkWkEoB?=	NWflPVI1TE2VTx?=	MlPlTWM2OD1zMT60O-KBkcL3TR?=	NGL6Sm49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUOwOFM5Oyd-MkWzNFQ{QDN:L3G+
SW620	NIPlPJFE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	M4rNOFAuOTBizszN	NHzafnozPOLCiXlCpC=>	Mn3hSG1UVw>?	NWXBTI9{UUN3ME2xNk4zPOLCidM1US=>	M{LGd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{C0N\|g{Lz5{NUOwOFM5OzxxYU6=
HCT116	NV\BWXpMS2WubDDWbYFjcWyrdImgRZN{[Xl?	MXewMVExKM7:TR?=	NIridGQzPOLCiXlCpC=>	NHyxeYZFVVOR	MVrJR\|UxRTJyLkS55qCKyrWP	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTNyNEO4N{c,OjV\|MESzPFM9N2F-
HaCaT	NUezcINYS2WubDDWbYFjcWyrdImgRZN{[Xl?	NWjz[\|M4OC5zL{GvNVAh\|ryP	NW\ZUIdoOjRiaB?=	MlTLSG1UVw>?	MWHk[YNz\WG\|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	NHOyW\|c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUKxNFc6PSd-MkWyNVA4QTV:L3G+
A5-RT3	M2\oOGNmdGxiVnnhZoltcXS7IFHzd4F6	M{nFV\|AvOS9zL{GwJO69VQ>?	M1O4O\|I1KGh?	MYTEUXNQ	MY\k[YNz\WG\|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJzMEe5OUc,OjV{MUC3PVU9N2F-
HaCaT	NVj3SpB5TnWwY4Tpc44hSXO\|YYm=	NEfIO4cyOOLCid88US=>	NXrwe4ZMOjRxNEigbC=>	NV\HWm5kTE2VTx?=	NXXMNIczcW6mdXPld{BOVVBiYX7kJGRPSSCocnHncYVvfGG2aX;u	M4O2OlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkGwO\|k2Lz5{NUKxNFc6PTxxYU6=
A5-RT3	M4m3eWZ2dmO2aX;uJGF{e2G7	MkHlNVDjiIoQvF2=	NUH0PFZiOjRxNEigbC=>	MWHEUXNQ	MkTNbY5lfWOnczDNUXAh[W6mIFTORUBnemGpbXXueIF1cW:w	NIPpdFA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUKxNFc6PSd-MkWyNVA4QTV:L3G+
A5-RT3	MVPGeY5kfGmxbjDBd5NigQ>?	M4LZZVUh\|ryP	NGD6ZWQ3KGh?	M1PxbGROW09?	MWXpcoR2[2W\|IITo[UBz\WynYYPlJI9nKG2rdH;jbI9v\HKrYXygdJJwfGWrboOgZY5lKHKnZIXj[ZMh[2yxbn;n[Y5q[yC\|dYL2bZZidCCrbjDhJINie3Cjc3WtbY5l\XCnbnTlcpQhdWGwbnXy	M37JXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkGwO\|k2Lz5{NUKxNFc6PTxxYU6=
U266	NY\nN4F3TnWwY4Tpc44hSXO\|YYm=	NULFWI5LPTByL{e1NEBvVQ>?	MXiyOE81QCCq	NHTMbItFVVOR	NG\XTI5ld3ewcnXneYxifGW\|IFLpcUwheHKrbnPpdIFtdHlidHjlJGVNKGm\|b3\vdo0>	NWrSeJVHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyNFg5QDhpPkK1NlA5QDh6PD;hQi=>
RPMI8226	M1jEUmZ2dmO2aX;uJGF{e2G7	M3\KWlUxOC95NUCgcm0>	M1jJcFI1NzR6IHi=	NV;Mbm9WTE2VTx?=	NGnnNpdld3ewcnXneYxifGW\|IFLpcUwheHKrbnPpdIFtdHlidHjlJGVNKGm\|b3\vdo0>	NIq5U4Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUKwPFg5QCd-MkWyNFg5QDh:L3G+
MM.1S	M1vINmZ2dmO2aX;uJGF{e2G7	NULFUpltPTByL{e1NEBvVQ>?	NVL6cWZ{OjRxNEigbC=>	M1Ta[GROW09?	M2ficIRwf26{ZXf1cIF1\XNiQnntMEBxemmwY3nwZYxtgSC2aHWgSWwhcXOxZn;ycS=>	MnzIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{MEi4PFgoRjJ3MkC4PFg5RC:jPh?=
Clone A	MlrsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXzMWIduOC5{4pETOlAh\|ryP	MoLJO\|IhcA>?	NHTNOotFVVOR	M4[0R2lEPTB;Nz61JO69VQ>?	M{PPVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkC4PFgzLz5{NUKwPFg5OjxxYU6=
CX-1	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHX2OlYxNjMkgKO2NEDPxE1?	MX[3NkBp	NWjsS\|dnTE2VTx?=	MlXNTWM2OD1zLkig{txO	NWi4TVg5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyNFg5QDJpPkK1NlA5QDh{PD;hQi=>
LS174T	NHnvRWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2rBUVAvOuLCk{[wJO69VQ>?	Mn20O\|IhcA>?	Mm\zSG1UVw>?	MmDyTWM2OD1zOD6zJO69VQ>?	NGqxUGQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUKwPFg5Oid-MkWyNFg5QDJ:L3G+
HT29	NWrwNZNMSXCxcITvd4l{KEG\|c3H5	MlPiNU82NzFyIN88US=>	NYTpVJBwPDhiaB?=		MoL6Z4F2e2W\|IHPlcIwh\GWjdHigbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	NH\Z[Zo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUG5NlE5QCd-MkWxPVIyQDh:L3G+
SW480	MXLBdI9xfG:\|aYOgRZN{[Xl?	MkDRNU82NzFyIN88US=>	MnriOFghcA>?		M3n2Z4NifXOnczDj[YxtKGSnYYToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	NGP4T\|Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUG5NlE5QCd-MkWxPVIyQDh:L3G+
Colo205	M2SwW2Fxd3C2b4Ppd{BCe3OjeR?=	MlrMNU82NzFyIN88US=>	NWLLd4tEPDhiaB?=		NG\HSplk[XW\|ZYOgZ4VtdCCmZXH0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF7MkG4PEc,OjVzOUKxPFg9N2F-
Caco2	MXvBdI9xfG:\|aYOgRZN{[Xl?	M2f6OlEwPS9zMDFOwG0>	NYTKbIQyPDhiaB?=		M4jYOYNifXOnczDj[YxtKGSnYYToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	M2XENFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUmyNVg5Lz5{NUG5NlE5QDxxYU6=
PCI-13	MoX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MVm3NkBp	M2nsRWROW09?	M{HwR2dKPTB;MUWgxtEhOS56IN88US=>	NW\zWFM2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxN\|k{QDdpPkK1NVM6Ozh5PD;hQi=>
PCI-15B	Ml3kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NG\a[Is4OiCq	Mn7HSG1UVw>?	NUS2T4pMT0l3ME2xNUDDuSB2LkWg{txO	M{jNWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUO5N\|g4Lz5{NUGzPVM5PzxxYU6=
UM-SCC22B	Mn;GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M2nrdVczKGh?	NVe5Z\|N6TE2VTx?=	MYDHTVUxRTF7INMxJFIvQSEQvF2=	NU\XT2FqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxN\|k{QDdpPkK1NVM6Ozh5PD;hQi=>
UM-SCC47	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NWC1fnkyPzJiaB?=	NHLxVXZFVVOR	NF35bVlIUTVyPUG5JOKyKDF{LkOg{txO	NG\Od2c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUGzPVM5Pyd-MkWxN\|k{QDd:L3G+
93-VU-147T	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NIfafHM4OiCq	M1n0XGROW09?	NIX2NYdIUTVyPUSuN{DDuSB\|LkWg{txO	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF\|OUO4O{c,OjVzM{mzPFc9N2F-
UD-SCC2	M2HzT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NFHoUZA4OiCq	MoHiSG1UVw>?	MWLHTVUxRTJ6INMxJFIvQSEQvF2=	NGrH[no9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUGzPVM5Pyd-MkWxN\|k{QDd:L3G+
UPCI:SCC90	NXnnc5J4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MoPLO\|IhcA>?	M1;rTmROW09?	NVnKcoZKT0l3ME22MlYhyrFiMT61JO69VQ>?	NWfJO5NORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxN\|k{QDdpPkK1NVM6Ozh5PD;hQi=>
RPMI-8226	MkjOR4VtdCCYaXHibYxqfHliQYPzZZk>	NXzZZ4c1OTJ3L{K1NE82ODBibl2=	NUXPSGFwPDiqwrC=	MVfEUXNQ	MV;k[YNz\WG\|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTByOEKwNkc,OjVyMEiyNFI9N2F-
OPM-2	M2fFU2NmdGxiVnnhZoltcXS7IFHzd4F6	Mn;wNVI2NzJ3MD:1NFAhdk1?	NXn2W4dUPDiqwrC=	NVXWNXVCTE2VTx?=	NY\mcWNR\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	NUjyfYx6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwNFgzODJpPkK1NFA5OjB{PD;hQi=>
RPMI-8226	MlS5RZBweHSxc3nzJGF{e2G7	NEnVdIcyOjVxMkWwM\|UxOCCwTR?=	MUG0PIjDqA>?	MoLxSG1UVw>?	M1q4[olv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	M160cVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEC4NlAzLz5{NUCwPFIxOjxxYU6=
OPM-2	NYrINlVQSXCxcITvd4l{KEG\|c3H5	MoDtNVI2NzJ3MD:1NFAhdk1?	NX\EN\|BJPDiqwrC=	MmrsSG1UVw>?	M4\PNIlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	M{XLflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEC4NlAzLz5{NUCwPFIxOjxxYU6=
COG-LL-319	NXL6Z5N1TnWwY4Tpc44hSXO\|YYm=	NEf3fnMyODBibl2=	MnSyNU8{NzZiaB?=	Mn3kSG1UVw>?	NVzadJNrcW6mdXPld{Bk[XOyYYPlMYRmeGWwZHXueEBO[2xvMTDjcIVifmGpZR?=	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl3MUS3Nkc,OjR7NUG0O\|I9N2F-
RS4;11	NYnvclJPTnWwY4Tpc44hSXO\|YYm=	MWGxNFAhdk1?	NWS5[JRwOS9\|L{[gbC=>	MXHEUXNQ	M3vITIlv\HWlZYOgZ4F{eGG\|ZT3k[ZBmdmSnboSgUYNtNTFiY3zlZZZi\2V?	MkTUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7NUG0O\|IoRjJ2OUWxOFczRC:jPh?=
FL5.12	MoHqSpVv[3Srb36gZZN{[Xl?				M2W4ZnJmfmW{c3HsJI9nKGO7dH;rbY5mKHerdHjkdoF4[WxicILveIVkfGmxbjDpckBKVDNiZHXw[Y5l\W62IFLjcFIhd3[ncnX4dJJme3OrbnegcY92e2ViRly1MlEzKGOnbHzzJIlvKHC{ZYPlcoNmKG:oIHLveolv\SCpZXzheIlvNCCHQ{WwJF0hOC5yMEig{txONg>?	NEjlfY49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{K1Olg{PCd-MUeyOVY5OzR:L3G+
DoHH2	M3jFSmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7				NGjTcJdKdmirYnn0bY9vKG:oIHPlcIwh\3Kxd4ToJIlvKGi3bXHuJGRwUEh{IHPlcIx{KG:4ZYLlfJBz\XO\|aX7nJGJkdDJiaX6gdJJme2WwY3Wgc4YhOyViRlLTMEBGSzVyIE2gNE4xODh\|IN88UU4>	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzJ3NkizOEc,OTd{NU[4N\|Q9N2F-
RS11380	NXuwdIt{T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=				MVTJcohq[mm2aX;uJI9nKGOnbHyg[5Jwf3SqIHnuJIh2dWGwIGLTNVE{QDBiY3XscJMhd3[ncnX4dJJme3OrbnegRoNtOiCrbjDwdoV{\W6lZTDv[kA{LSCIQmOsJGVEPTBiPTCwMlAyPCEQvF2u	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzJ3NkizOEc,OTd{NU[4N\|Q9N2F-
FL5.12	MYjGeY5kfGmxbjDhd5NigQ>?				NUf3WoxFWmW4ZYLzZYwhd2ZiY4n0c4tqdmVid3n0bIRz[XejbDDwdo91\WO2aX;uJIlvKEmOMzDk[ZBmdmSnboSgRoNtNXiOIH;2[ZJmgHC{ZYPzbY5oKG2xdYPlJGZNPS5zMjDj[YxteyCrbjDwdoV{\W6lZTDv[kBjd3[rbnWg[4Vt[XSrbjygSWM2OCB;IECuNFMh\|ryPLh?=	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzJ3NkizOEc,OTd{NU[4N\|Q9N2F-
FL5.12	MXzGeY5kfGmxbjDhd5NigQ>?				NUPaZ5BMWmW4ZYLzZYwhd2ZiY4n0c4tqdmVid3n0bIRz[XejbDDwdo91\WO2aX;uJIlvKEmOMzDk[ZBmdmSnboSgRoNtOiCxdnXy[ZhxemW\|c3nu[{Bud3W\|ZTDGUFUvOTJiY3XscJMhcW5icILld4Vv[2Vib3[gN{UhTkKVLDDFR\|UxKD1iMD6wOUDPxE1w	NHmxT4g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{K1Olg{PCd-MUeyOVY5OzR:L3G+
DoHH2	MoH0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?				NWXCZVJjUW6qaXLpeIlwdiCxZjDj[YxtKGe{b4f0bEBqdiCqdX3hckBFd0iKMjDj[YxteyCxdnXy[ZhxemW\|c3nu[{BD[2x{IHnuJJBz\XOnbnPlJI9nKDFyJTDIV{whTUN3MDC9JFAvOTNizszNMi=>	NIPaOIU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{K1Olg{PCd-MUeyOVY5OzR:L3G+
RS11380	NF7mO5NIem:5dHigbY5pcWKrdHnvckBie3OjeR?=				MYfJcohq[mm2aX;uJI9nKGOnbHyg[5Jwf3SqIHnuJIh2dWGwIGLTNVE{QDBiY3XscJMhd3[ncnX4dJJme3OrbnegRoNtOiCrbjDwdoV{\W6lZTDv[kAyOCViSGOsJGVEPTBiPTCwMlE2KM7:TT6=	NG\5eY49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{K1Olg{PCd-MUeyOVY5OzR:L3G+
SUDHL4	NVnrT\|NLT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=				NHnRUXdKdmirYnn0bY9vKG:oIHPlcIwh\3Kxd4ToJIlvKGi3bXHuJHNWTEiONDDj[YxteyCxdnXy[ZhxemW\|c3nu[{BD[2x{IHnuJJBz\XOnbnPlJI9nKDNnIF\CV{whTUN3MDC9JFAvOjJizszNMi=>	M3[4VFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5MkW2PFM1Lz5zN{K1Olg{PDxxYU6=
FL5.12	M2TpfmZ2dmO2aX;uJIF{e2G7				MlHHVoV3\XK\|YXygc4Yh[3m2b3vpcoUhf2m2aHTyZZdidCCycn;0[YN1cW:wIHnuJGlNOyCmZYDlcoRmdnRiQnPsMZhNKG:4ZYLlfJBz\XO\|aX7nJI1wfXOnIF\MOU4yOiClZXzsd{BqdiCycnXz[Y5k\SCxZjCzKUBHSlNuIFXDOVAhRSByLkKyJO69VS5?	NYLJVJQ2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUeyOVY5OzRpPkG3NlU3QDN2PD;hQi=>
SUDHL4	MmKyS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?				NEPUR\|JKdmirYnn0bY9vKG:oIHPlcIwh\3Kxd4ToJIlvKGi3bXHuJHNWTEiONDDj[YxteyCxdnXy[ZhxemW\|c3nu[{BD[2x{IHnuJJBz\XOnbnPlJI9nKDFyJTDIV{whTUN3MDC9JFAvQDVizszNMi=>	NVrGU\|VZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUeyOVY5OzRpPkG3NlU3QDN2PD;hQi=>
FL5.12	MoPqR5l1d3SxeHnjbZR6KGG\|c3H5		NYHUWJRDOjRiaILz		NVm0fJpnS3m2b4TvfIlkcXS7IHHnZYlve3RiSVyzMYRmeGWwZHXueEBud3W\|ZTDGUFUvOTJiY3XscJMhd3[ncnX4dJJme3OrbnegbJVu[W5iQnPsNkBie3Onc4Pl[EBieyClZXzsJJZq[WKrbHn0fUBi\nSncjCyOEBpenNiYomgUXRUKGG\|c3H5JIlvKGGkc3XuZ4Uhd2Zic3XyeY0tKEWFNUCgQUAxNjByN{eg{txONg>?	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDh2MUi4Nkc,OTh6NEG4PFI9N2F-
FL5.12	MoTnR5l1d3SxeHnjbZR6KGG\|c3H5		Mo\vNlQhcHK\|		NXixXopIS3m2b4TvfIlkcXS7IHHnZYlve3RiSVyzMYRmeGWwZHXueEBud3W\|ZTDGUFUvOTJiY3XscJMhd3[ncnX4dJJme3OrbnegbJVu[W5iQnPsMXhNKGG\|c3Xzd4VlKGG\|IHPlcIwhfmmjYnnsbZR6KGGodHXyJFI1KGi{czDifUBOXFNiYYPzZZkhcW5iYXLz[Y5k\SCxZjDz[ZJ2dSxiRVO1NEA:KDBwMEOg{txONg>?	NHnaNoo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEi0NVg5Oid-MUi4OFE5QDJ:L3G+
NCI-H146	MmLDR5l1d3SxeHnjbZR6KGG\|c3H5		MlLzOFghcHK\|		M3PxNWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG5EUS2KMUS2JINmdGy\|IHHzd4V{e2WmIHHzJINmdGxidnnhZoltcXS7IHHmeIVzKDR6IHjyd{BqdiCycnXz[Y5k\SCxZjCxNEUhcHWvYX6gd4VzfW1uIFXDOVAhRSByLkC4O{DPxE1w	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDh2MUi4Nkc,OTh6NEG4PFI9N2F-
CLL	NHzhV\|JCeG:ydH;zbZMh[XO\|YYm=				MnTRTY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDoeY1idiCFTFygZ4VtdHNuIFXDOVAhRSByLkCwOFUh\|ryPLh?=	NYLIUWh5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC5NlU1OzNpPkKwPVI2PDN\|PD;hQi=>
MEF	NVviVVU6S3m2b4TvfIlkcXS7IHHzd4F6		NUnYOnJ3OjRiaILz		NXPnd\|E1S3m2b4TvfIlkcXS7IHHnZYlve3RibX;1d4UhdWOuLUGg[IVncWOrZX70JG1GTiClZXzsd{Bi\nSncjCyOEBpenNiYomgR4VtdCC2aYTldkBodG9iYYPzZZkhcW5icILld4Vv[2Vib3[gNUUhe2W{dX2sJGVEPTBiPTCwMlAxOjB\|IN88UU4>	NIG0bmg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUO2OlI6PSd-MkGzOlYzQTV:L3G+
MEF	Mki5R5l1d3SxeHnjbZR6KGG\|c3H5		NXr3S4JLOjRiaILz		NEm4dVBEgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBu[2xvMTDk[YZq[2mnboSgUWVHKGOnbHzzJIFnfGW{IEK0JIhzeyCkeTDD[YxtKHSrdHXyJIdtdyCjc4PhfUBqdiCycnXz[Y5k\SCxZjCxNEUhe2W{dX2sJGVEPTBiPTCwMlA2OSEQvF2u	NIDKO3U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUO2OlI6PSd-MkGzOlYzQTV:L3G+
MEF	NHTjXYJEgXSxdH;4bYNqfHliYYPzZZk>		NEXRdmwzPCCqcoO=		MnnhR5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgcYNtNTFiZHXmbYNq\W62IF3FSkBk\WyuczDh[pRmeiB{NDDodpMh[nliQ3XscEB1cXSncjDncI8h[XO\|YYmgbY4heHKnc3XuZ4Uhd2ZiMUClJIZmfGGuIHLveolv\SC\|ZYL1cUwhTUN3MDC9JFAvODVzIN88UU4>	NXXJTY5lRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGzOlYzQTVpPkKxN\|Y3Ojl3PD;hQi=>
RS4:11	NFW3OHZCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=				M3PMSGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iUmO0PlEyKGOnbHzzJIlvKHC{ZYPlcoNmKG:oIEGwKUBpfW2jbjDz[ZJ2dSxiRVO1NEA:KDBwMEK0JO69VS5?	NIXV[ZA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEmyOlI1Pyd-Mki5NlYzPDd:L3G+
MOLT4	M2rK[mFvfGmycn;sbYZmemG2aY\lJIF{e2G7				Mnj5RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPT1zUOEBk\WyuczDpckBxemW\|ZX7j[UBw\iBzMDWgbJVu[W5ic3XyeY0tKEWFNUCgQUAxNjZ{MjFOwG0v	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDl{NkK0O{c,Ojh7Mk[yOFc9N2F-
Jurkat	NEL4[ZFEgXSxdH;4bYNqfHliYYPzZZk>		M{\oVVQ5KGi{cx?=		MkjPR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTpVzc2G2IHPlcIx{KGGodHXyJFQ5KGi{czDifUBk\WyuIITpeIVzNWKudXWgZZN{[XluIFnDOVAhRSBzLkO4JO69VS5?	MmKzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl5NEO4OVgoRjF7N{SzPFU5RC:jPh?=
HCT116	M4D0UmN6fG:2b4jpZ4l1gSCjc4PhfS=>		M1rrRVQ5KGi{cx?=		Ml3ER5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTGNVOTF4IHPlcIx{KGGodHXyJFQ5KGi{czDifUBk\WyuIITpeIVzNWKudXWgZZN{[XluIFnDOVAhRSB2LkC2JO69VS5?	NVX5U2VSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm3OFM5PThpPkG5O\|Q{QDV6PD;hQi=>
SU-8686	NVXydW5lS3m2b4TvfIlkcXS7IHHzd4F6		MUi0PEBpenN?		M1rHd2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHNWNTh4OE[gZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KGOnbHygeIl1\XJvYnz1[UBie3OjeTygTWM2OCB;IESuNlQh\|ryPLh?=	M13mOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7N{SzPFU5Lz5zOUe0N\|g2QDxxYU6=
H460	NIrrfnVEgXSxdH;4bYNqfHliYYPzZZk>		NGLTWpM1QCCqcoO=		Mo[5R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTFQ3OCClZXzsd{Bi\nSncjC0PEBpenNiYomgZ4VtdCC2aYTldk1jdHWnIHHzd4F6NCCLQ{WwJF0hQC5yMzFOwG0v	NILwdFM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUe0N\|g2QCd-MUm3OFM5PTh:L3G+
Hepa-1c1c7	MXzDfZRwfG:6aXPpeJkh[XO\|YYm=		MVO0PEBpenN?		NWHie25[S3m2b4TvfIlkcXS7IHHnZYlve3RibX;1d4UhUGWyYT2xZ\|FkPyClZXzsd{Bi\nSncjC0PEBpenNiYomgZ4VtdCC2aYTldk1jdHWnIHHzd4F6NCCLQ{WwJF0hQC54ODFOwG0v	NXHjeo5[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm3OFM5PThpPkG5O\|Q{QDV6PD;hQi=>
MCF7	M13FcWN6fG:2b4jpZ4l1gSCjc4PhfS=>		MVq0PEBpenN?		MYDDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDj[YxtKHSrdHXyMYJtfWViYYPzZZktKEmFNUCgQUAzOS5{NjFOwG0v	M4f2[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7N{SzPFU5Lz5zOUe0N\|g2QDxxYU6=
DU145	MU\DfZRwfG:6aXPpeJkh[XO\|YYm=		MV:0PEBpenN?		M1PqdmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGRWOTR3IHPlcIx{KGGodHXyJFQ5KGi{czDifUBk\WyuIITpeIVzNWKudXWgZZN{[XluIFnDOVAhRSB{Nz62JO69VS5?	Mm\4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl5NEO4OVgoRjF7N{SzPFU5RC:jPh?=
HCT116	NY[ycJpCS3m2b4TvfIlkcXS7IHHzd4F6		MnXkO\|IhcHK\|		NXvKNXpWS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUEOWMUG2JINmdGy\|IHX4dJJme3OrbnegRoNtNXiOLDDCZ4wuOiCjbnSgUYNtNTFiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDR5Lkeg{txONg>?	M1fMSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MUeyO\|AyLz5{MkG3NlcxOTxxYU6=
BL21 (DE3)	M3TuS2Z2dmO2aX;uJIF{e2G7		NFTwe\|YzKGi{cx?=		NILmOI5DcW6maX7nJIFn\mmwaYT5JJRwKE5vdHXycYlvfXNiNmigTIl{NXSjZ3fl[EBpfW2jbjDCZ4wzKGW6cILld5Nm\CCrbjDFd4Np\XKrY3jpZUBkd2yrIFLMNlEhMESHMzmgZ4VtdHNiYX\0[ZIhOiCqcoOgZpkh\my3b4Lld4NmdmOnIIDvcIFzcXqjdHnvckBie3OjeTygTWM2OCB;IECuNFAzKM7:TT6=	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjR2OEm4PEc,OjJ2NEi5PFg9N2F-
BL21 (DE3)	MV7GeY5kfGmxbjDhd5NigQ>?		NX\zWlhZOiCqcoO=		M4Tkb2JqdmSrbnegZYZncW6rdImgeI8hVi22ZYLtbY52eyB6WDDIbZMufGGpZ3XkJIh2dWGwIFLjcE15VCCneIDy[ZN{\WRiaX6gSZNkcGW{aXPobYEh[2:uaTDCUFIyKCiGRUOpJINmdGy\|IHHmeIVzKDJiaILzJIJ6KG[udX;y[ZNk\W6lZTDwc4xiemm8YYTpc44h[XO\|YYmsJGlEPTBiPTCwMlAxPiEQvF2u	MoXBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ2NEi5PFgoRjJ{NES4PVg5RC:jPh?=
NCI-H146	M{Lo[Wdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NHHnPZk1KGSjeYO=		MWfHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDOR2kuUDF2NjDj[YxteyCjZoTldkA1KGSjeYOgZpkhX1OWODDhd5NigSxiSVO1NEA:KDBwMEm3JO69VS5?	MljUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ2NEi5PFgoRjJ{NES4PVg5RC:jPh?=
NCI-H1417	MWfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NIHhdVQ1KGSjeYO=		MVjHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDOR2kuUDF2MUegZ4VtdHNiYX\0[ZIhPCCmYYnzJIJ6KFeVVEigZZN{[XluIFnDOVAhRSByLkGzJO69VS5?	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjR2OEm4PEc,OjJ2NEi5PFg9N2F-
CCRF-CEM	MWjDfZRwfG:6aXPpeJkh[XO\|YYm=		MXq0PEBpenN?		NU[2b246S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hS0OURj3DSW0h[2WubIOgZZN{\XO\|ZXSgZZMh[2WubDD2bYFjcWyrdImgZYZ1\XJiNEigbJJ{KGK7IHPlcIx1cXSncj3icJVmKGG\|c3H5MEBKSzVyIE2gNE44PCEQvF2u	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjV6Mkm5NUc,OjJ3OEK5PVE9N2F-
HL60	M2LF[GN6fG:2b4jpZ4l1gSCjc4PhfS=>		MnzwOFghcHK\|		NFLpXItEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJVDZyIHPlcIx{KGG\|c3Xzd4VlKGG\|IHPlcIwhfmmjYnnsbZR6KGGodHXyJFQ5KGi{czDifUBk\WyudHn0[ZIu[my3ZTDhd5NigSxiSVO1NEA:KDBwN{[g{txONg>?	NYW5eYk4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK1PFI6QTFpPkKyOVgzQTlzPD;hQi=>
K562	M4HyXWN6fG:2b4jpZ4l1gSCjc4PhfS=>		MV20PEBpenN?		MmqxR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gT\|U3OiClZXzsd{Bie3Onc4Pl[EBieyClZXzsJJZq[WKrbHn0fUBi\nSncjC0PEBpenNiYomgZ4VtdHSrdHXyMYJtfWViYYPzZZktKEmFNUCgQUA{PC55IN88UU4>	M1zV[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NUiyPVkyLz5{MkW4Nlk6OTxxYU6=
NCI-H146	Mn3iRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MnvFOEBl[Xm\|		NI\FO\|NCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF7DTU1JOTR4IHPlcIx{KGGodHXyJFQh\GG7czDifUBYW1R6IHHzd4F6NCCLQ{WwJF0hOC5yM{eg{txONg>?	NXTvXlVrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK3OFc2QThpPkKyO\|Q4PTl6PD;hQi=>
NCI-H1963	NUnkbotlSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		Mn7sOEBl[Xm\|		MX7BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE6FST3INVk3OyClZXzsd{Bi\nSncjC0JIRigXNiYomgW3NVQCCjc4PhfUwhUUN3MDC9JFAvODV7IN88UU4>	NUfaTmE2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK3OFc2QThpPkKyO\|Q4PTl6PD;hQi=>
NCI-H1417	MVrBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NYLZRWJCPCCmYYnz		MlOzRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCQQ1mtTFE1OTdiY3XscJMh[W[2ZYKgOEBl[Xm\|IHL5JHdUXDhiYYPzZZktKEmFNUCgQUAxNjRzMjFOwG0v	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjd2N{W5PEc,OjJ5NEe1PVg9N2F-
RS4:11	M1H4PGFxd3C2b4Ppd{Bie3OjeR?=		NGHZVpo1QCCqcoO=		NIn4XpRKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m\|IHnuJGJkdDJiZHXw[Y5l\W62IHj1cYFvKFKVNEqxNUBk\WyuczDh[pRmeiB2ODDodpMh[nliQX7u[ZhqdiCYIIP0ZYlvcW6pIHLhd4VlKG[ub4egZ5l1d22ndIL5MEBKSzVyIE2gNE4zPyEQvF2u	M{[5c\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{G0NFU1Lz5{M{OxOFA2PDxxYU6=
K562	NGDCPJJCeG:ydH;zbZMh[XO\|YYm=		MWO0PEBpenN?		NVHicpFyUW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBO[2xzIHTldIVv\GWwdDDoeY1idiCNNU[yJINmdGy\|IHHmeIVzKDR6IHjyd{BjgSCDbn7lfIlvKFZic4ThbY5qdmdiYnHz[YQh\myxdzDjfZRwdWW2comsJGlEPTBiPTCxOk41KM7:TT6=	NUX6UXNiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzNVQxPTRpPkKzN\|E1ODV2PD;hQi=>
NCI-H1963	MWPDfZRwfG:6aXPpeJkh[XO\|YYm=		NGXifVU1KGSjeYO=		MWrDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDOR2kuUDF7NkOgZ4VtdHNiYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiNDDkZZl{KGK7IGfTWEBie3OjeTygTWM2OCB;IECuNFU1KM7:TT6=	MlPPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2NEiyPVgoRjJ\|NES4Nlk5RC:jPh?=
NCI-H187	M4\J[GN6fG:2b4jpZ4l1gSCjc4PhfS=>		NXLEO5FSPCCmYYnz		M{fJWWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG5EUS2KMUi3JINmdGy\|IHHzd4V{e2WmIHHzJIdzd3e2aDDpcohq[mm2aX;uJIFnfGW{IESg[IF6eyCkeTDXV3Qh[XO\|YYmsJGlEPTBiPTCwMlE{PzdizszNMi=>	Mlm2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2NEiyPVgoRjJ\|NES4Nlk5RC:jPh?=
NCI-H1417	MnXoR5l1d3SxeHnjbZR6KGG\|c3H5		NGfOR3M1KGSjeYO=		MlrNR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUmNKNUhzNEG3JINmdGy\|IHHzd4V{e2WmIHHzJIdzd3e2aDDpcohq[mm2aX;uJIFnfGW{IESg[IF6eyCkeTDXV3Qh[XO\|YYmsJGlEPTBiPTCwMlE4OzRizszNMi=>	NIfsUnc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{S0PFI6QCd-MkO0OFgzQTh:L3G+
HL60	NETjdFdIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NIfQc5g4OiCqcoO=		MmXYS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gTGw3OCClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gNE46PyEQvF2u	NGrjUlU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{exNlk{QSd-Mke3NVI6Ozl:L3G+
MCF7	MVvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NID2enM4OiCqcoO=		MkKxS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gUWNHPyClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gNlUvOzNizszNMi=>	Ml\jQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd5MUK5N\|koRjJ5N{GyPVM6RC:jPh?=
U266	MkHES5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MW[3NkBpenN?		NHnhc4NIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBWOjZ4IHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUAzPy5\|NTFOwG0v	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzdzMkmzPUc,Ojd5MUK5N\|k9N2F-
SKOV3	NInvXoZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NUnucIJHPzJiaILz		MnXHS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gV2tQXjNiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFQ3NjV7IN88UU4>	M4GwS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5N{GyPVM6Lz5{N{exNlk{QTxxYU6=
RS4:11	MUfDfZRwfG:6aXPpeJkh[XO\|YYm=		NX7oTZNUOjRiaILz		MXLDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDSV\|Q7OTFiY3XscJMh[XO\|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJINmdGxidnnhZoltcXS7IHHmeIVzKDJ2IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSByLkOzJO69VS5?	M2roN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEWzNVM2Lz5{OUS1N\|E{PTxxYU6=
Remb1	M3;XdWN6fG:2b4jpZ4l1gSCjc4PhfS=>		Mki4NlQhcHK\|		NVX1Xo1HS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hWmWvYkGgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKGOnbHygeoli[mmuaYT5JIFnfGW{IEK0JIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCxMlQh\|ryPLh?=	MlTKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2NUOxN\|UoRjJ7NEWzNVM2RC:jPh?=
BL21	M2LrPWZ2dmO2aX;uJIF{e2G7	MYGxNEB2VQ>?	MW[zJIhzew>?		NEfTcYpFcXOybHHj[Y1mdnRib3[gRm9FUVC\LVLhb{Bkd26sdXfheIVlKHCncITp[IUh\nKxbTDHV3QufGGpZ3XkJIh2dWGwIFLjcE0zNWyra3WgdJJwfGWrbjCxJGcyQT[DIH31eIFvfCCneIDy[ZN{\WRiaX6gSZNkcGW{aXPobYEh[2:uaTDCUFIyKGOnbHzzJIF1KDFyIIXNJIFnfGW{IEOgbJJ{KGK7IH\seY9z\XOlZX7j[UBxd2yjcnn6ZZRqd25iY3;tdIV1cXSrb36gZZN{[XluIFvpJF0hOC5yMEGg{txONg>?	M3;nSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOEC3OVEzLz5{MUiwO\|UyOjxxYU6=
BL21	M4n1T2Z2dmO2aX;uJIF{e2G7	MXexNEB2VQ>?	NEC0PHE{KGi{cx?=		MU\EbZNxdGGlZX3lcpQhd2ZiQl;ETXB[NUKjazDjc45rfWejdHXkJJBmeHSrZHWg[pJwdSCJU2SteIFo\2WmIHj1cYFvKEKlbD2yMYxqc2VicILveIVqdiBzIFG5N3YhdXW2YX70JIV5eHKnc4Pl[EBqdiCHc3Po[ZJq[2irYTDjc4xqKEKOMkGgZ4VtdHNiYYSgNVAhfU1iYX\0[ZIhOyCqcoOgZpkh\my3b4Lld4NmdmOnIIDvcIFzcXqjdHnvckBkd22yZYTpeIlwdiCjc4PhfUwhU2liPTCwMlAxOTRizszNMi=>	MlTlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF6MEe1NVIoRjJzOEC3OVEzRC:jPh?=
BL21	NHW3bFRHfW6ldHnvckBie3OjeR?=	MWqxNEB2VQ>?	MojKN{BpenN?		NEXTcmNFcXOybHHj[Y1mdnRib3[gRm9FUVC\LVLhb{Bkd26sdXfheIVlKHCncITp[IUh\nKxbTDHV3QufGGpZ3XkJIh2dWGwIFLjcE0zNWyra3WgdJJwfGWrbjCxJHkyQTWIIH31eIFvfCCneIDy[ZN{\WRiaX6gSZNkcGW{aXPobYEh[2:uaTDCUFIyKGOnbHzzJIF1KDFyIIXNJIFnfGW{IEOgbJJ{KGK7IH\seY9z\XOlZX7j[UBxd2yjcnn6ZZRqd25iY3;tdIV1cXSrb36gZZN{[XluIFvpJF0hOC5yMEG1JO69VS5?	M3XkTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOEC3OVEzLz5{MUiwO\|UyOjxxYU6=
BL21	NE\6dWlHfW6ldHnvckBie3OjeR?=	NU\ZXXpkOTBidV2=	NYPEfVlmOyCqcoO=		NHj6NmVFcXOybHHj[Y1mdnRib3[gRm9FUVC\LVLhb{Bkd26sdXfheIVlKHCncITp[IUh\nKxbTDHV3QufGGpZ3XkJIh2dWGwIGfpcIQhfHmyZTDCZ4wuOi2uaXvlJJBzd3SnaX6gNUBmgHC{ZYPz[YQhcW5iRYPjbIVzcWOqaXGgZ49tcSCETEKxJINmdGy\|IHH0JFExKHWPIHHmeIVzKDNiaILzJIJ6KG[udX;y[ZNk\W6lZTDwc4xiemm8YYTpc44h[2:vcHX0bZRqd25iYYPzZZktKEurIE2gNE4xODN2IN88UU4>	M2iwUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOEC3OVEzLz5{MUiwO\|UyOjxxYU6=
BL21	MYXGeY5kfGmxbjDhd5NigQ>?	NF7PZ5EyOCC3TR?=	M2TDe\|MhcHK\|		NUXHcZVjTGm\|cHzhZ4Vu\W62IH;mJGJQTEmSWT3CZYsh[2:waoXnZZRm\CCyZYD0bYRmKG[{b32gS3NVNXSjZ3fl[EBpfW2jbjDCZ4wuOi2uaXvlJJBzd3SnaX6gNUBGOTJ7SDDteZRidnRiZYjwdoV{e2WmIHnuJGV{[2incnnjbIliKGOxbHmgRmwzOSClZXzsd{BifCBzMDD1UUBi\nSncjCzJIhzeyCkeTDmcJVwemW\|Y3XuZ4UheG:uYYLpfoF1cW:wIHPvcZBmfGm2aX;uJIF{e2G7LDDLbUA:KDBwMEC0OUDPxE1w	NEmybXM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUiwO\|UyOid-MkG4NFc2OTJ:L3G+
BL21	NH;We\|RHfW6ldHnvckBie3OjeR?=	M3XIRVExKHWP	M{TrNFMhcHK\|		NXr1R\|I1TGm\|cHzhZ4Vu\W62IH;mJGJQTEmSWT3CZYsh[2:waoXnZZRm\CCyZYD0bYRmKG[{b32gS3NVNXSjZ3fl[EBpfW2jbjDCZ4wuOi2uaXvlJJBzd3SnaX6gNUBGQT[JIH31eIFvfCCneIDy[ZN{\WRiaX6gSZNkcGW{aXPobYEh[2:uaTDCUFIyKGOnbHzzJIF1KDFyIIXNJIFnfGW{IEOgbJJ{KGK7IH\seY9z\XOlZX7j[UBxd2yjcnn6ZZRqd25iY3;tdIV1cXSrb36gZZN{[XluIFvpJF0hOC5yMEW4JO69VS5?	NYS1d2xRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG4NFc2OTJpPkKxPFA4PTF{PD;hQi=>
BL21	NHzCUmVHfW6ldHnvckBie3OjeR?=	M{LFVFExKHWP	NV:5PXZ4OyCqcoO=		NIDnN\|ZFcXOybHHj[Y1mdnRib3[gRm9FUVC\LVLhb{Bkd26sdXfheIVlKHCncITp[IUh\nKxbTDHV3QufGGpZ3XkJIh2dWGwIFLjcE0zNWyra3WgdJJwfGWrbjCxJGEyPDKJZHXseIEyOz[WIH31eIFvfCCneIDy[ZN{\WRiaX6gSZNkcGW{aXPobYEh[2:uaTDCUFIyKGOnbHzzJIF1KDFyIIXNJIFnfGW{IEOgbJJ{KGK7IH\seY9z\XOlZX7j[UBxd2yjcnn6ZZRqd25iY3;tdIV1cXSrb36gZZN{[XluIFvpJF0hOC5yMTFOwG0v	NVuyRoxMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG4NFc2OTJpPkKxPFA4PTF{PD;hQi=>
BL21	MmnkSpVv[3Srb36gZZN{[Xl?	NI\ESHAyOCC3TR?=	MX2zJIhzew>?		M2\ET2Rqe3CuYXPlcYVvfCCxZjDCU2RKWFlvQnHrJINwdmq3Z3H0[YQheGWydHnk[UBnem:vIFfTWE11[WepZXSgbJVu[W5iQnPsMVIudGmtZTDwdo91\WmwIEGgRVE1OkdibYX0ZY51KGW6cILld5Nm\CCrbjDFd4Np\XKrY3jpZUBkd2yrIFLMNlEh[2WubIOgZZQhOTBidV2gZYZ1\XJiMzDodpMh[nliZnz1c5Jme2OnbnPlJJBwdGG{aYrheIlwdiClb33w[ZRqfGmxbjDhd5NigSxiS3mgQUAxNjB{MTFOwG0v	MkTUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF6MEe1NVIoRjJzOEC3OVEzRC:jPh?=
BL21	Mm\ySpVv[3Srb36gZZN{[Xl?	MkK0NVAhfU1?	MVmzJIhzew>?		M3vTeGRqe3CuYXPlcYVvfCCxZjDCU2RKWFlvQnHrJINwdmq3Z3H0[YQheGWydHnk[UBnem:vIFfTWE11[WepZXSgbJVu[W5iQnPsMVIudGmtZTDwdo91\WmwIEGgUFE{OFZibYX0ZY51KGW6cILld5Nm\CCrbjDFd4Np\XKrY3jpZUBkd2yrIFLMNlEh[2WubIOgZZQhOTBidV2gZYZ1\XJiMzDodpMh[nliZnz1c5Jme2OnbnPlJJBwdGG{aYrheIlwdiClb33w[ZRqfGmxbjDhd5NigSxiS3mgQUAxNjB3ODFOwG0v	NXfv[FhzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG4NFc2OTJpPkKxPFA4PTF{PD;hQi=>
BL21	MVHGeY5kfGmxbjDhd5NigQ>?	MXyxNEB2VQ>?	MkKxN{BpenN?		NF;Ld3pFcXOybHHj[Y1mdnRib3[gRm9FUVC\LVLhb{Bkd26sdXfheIVlKHCncITp[IUh\nKxbTDHV3QufGGpZ3XkJIh2dWGwIFLjcE0zNWyra3WgdJJwfGWrbjCxJIRmdHSjMUO2WEBufXSjboSg[ZhxemW\|c3XkJIlvKEW\|Y3jldolkcGmjIHPvcIkhSkx{MTDj[YxteyCjdDCxNEB2VSCjZoTldkA{KGi{czDifUBndHWxcnXzZ4Vv[2VicH;sZZJqgmG2aX;uJINwdXCndHn0bY9vKGG\|c3H5MEBMcSB;IECuNFYh\|ryPLh?=	M{LQSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOEC3OVEzLz5{MUiwO\|UyOjxxYU6=
BL21	MnTESpVv[3Srb36gZZN{[Xl?	M3jrXlExKHWP	M{GwflMhcHK\|		MY\EbZNxdGGlZX3lcpQhd2ZiQl;ETXB[NUKjazDjc45rfWejdHXkJJBmeHSrZHWg[pJwdSCJU2SteIFo\2WmIHj1cYFvKEKlbD2yMYxqc2VicILveIVqdiBzIFyxN\|BCKG23dHHueEBmgHC{ZYPz[YQhcW5iRYPjbIVzcWOqaXGgZ49tcSCETEKxJINmdGy\|IHH0JFExKHWPIHHmeIVzKDNiaILzJIJ6KG[udX;y[ZNk\W6lZTDwc4xiemm8YYTpc44h[2:vcHX0bZRqd25iYYPzZZktKEurIE2gNE4xPzNizszNMi=>	NYWzNGZpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG4NFc2OTJpPkKxPFA4PTF{PD;hQi=>
BL21	M2nZcWZ2dmO2aX;uJIF{e2G7	MUOxNEB2VQ>?	MXqzJIhzew>?		Mn3nSIl{eGyjY3Xt[Y51KG:oIFLPSGlRYS2EYXugZ49vcnWpYYTl[EBx\XC2aXTlJIZzd21iR2PUMZRi\2enZDDoeY1idiCEY3ytNk1tcWunIIDyc5RmcW5iMTDSNVAxTSCvdYThcpQh\XiycnXzd4VlKGmwIFXzZ4hmemmlaHnhJINwdGliQlyyNUBk\WyuczDheEAyOCC3TTDh[pRmeiB\|IHjyd{BjgSCobIXvdoV{[2WwY3WgdI9t[XKrenH0bY9vKGOxbYDleIl1cW:wIHHzd4F6NCCNaTC9JFAvOTZizszNMi=>	MmXkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF6MEe1NVIoRjJzOEC3OVEzRC:jPh?=
BL21	MXHGeY5kfGmxbjDhd5NigQ>?	Mn3mNVAhfU1?	MlrtN{BpenN?		MWTEbZNxdGGlZX3lcpQhd2ZiQl;ETXB[NUKjazDjc45rfWejdHXkJJBmeHSrZHWg[pJwdSCJU2SteIFo\2WmIHj1cYFvKEKlbD2yMYxqc2VicILveIVqdiBzIG[xOFFCKG23dHHueEBmgHC{ZYPz[YQhcW5iRYPjbIVzcWOqaXGgZ49tcSCETEKxJINmdGy\|IHH0JFExKHWPIHHmeIVzKDNiaILzJIJ6KG[udX;y[ZNk\W6lZTDwc4xiemm8YYTpc44h[2:vcHX0bZRqd25iYYPzZZktKEurIE2gNE4yQSEQvF2u	NGHmcFk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUiwO\|UyOid-MkG4NFc2OTJ:L3G+
BL21	MYnGeY5kfGmxbjDhd5NigQ>?	NV:0eVZYOTBidV2=	M3SzTlMhcHK\|		Ml3uSIl{eGyjY3Xt[Y51KG:oIFLPSGlRYS2EYXugZ49vcnWpYYTl[EBx\XC2aXTlJIZzd21iR2PUMZRi\2enZDDoeY1idiCEY3ytNk1tcWunIIDyc5RmcW5iMTDBNVQzXCCvdYThcpQh\XiycnXzd4VlKGmwIFXzZ4hmemmlaHnhJINwdGliQlyyNUBk\WyuczDheEAyOCC3TTDh[pRmeiB\|IHjyd{BjgSCobIXvdoV{[2WwY3WgdI9t[XKrenH0bY9vKGOxbYDleIl1cW:wIHHzd4F6NCCNaTC9JFAvOjdizszNMi=>	NHrJUmw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUiwO\|UyOid-MkG4NFc2OTJ:L3G+
BL21	NH;uSVBHfW6ldHnvckBie3OjeR?=	MmLuNVAhfU1?	M{nkXlMhcHK\|		MW\EbZNxdGGlZX3lcpQhd2ZiQl;ETXB[NUKjazDjc45rfWejdHXkJJBmeHSrZHWg[pJwdSCJU2SteIFo\2WmIHj1cYFvKEKlbD2yMYxqc2VicILveIVqdiBzIFyxN\|BIKG23dHHueEBmgHC{ZYPz[YQhcW5iRYPjbIVzcWOqaXGgZ49tcSCETEKxJINmdGy\|IHH0JFExKHWPIHHmeIVzKDNiaILzJIJ6KG[udX;y[ZNk\W6lZTDwc4xiemm8YYTpc44h[2:vcHX0bZRqd25iYYPzZZktKEurIE2gNE4zQSEQvF2u	M4fBbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOEC3OVEzLz5{MUiwO\|UyOjxxYU6=
BL21	Mm\ESpVv[3Srb36gZZN{[Xl?	NH[1cI4yOCC3TR?=	MYezJIhzew>?		NYDvPWxpTGm\|cHzhZ4Vu\W62IH;mJGJQTEmSWT3CZYsh[2:waoXnZZRm\CCyZYD0bYRmKG[{b32gS3NVNXSjZ3fl[EBpfW2jbjDCZ4wuOi2uaXvlJJBzd3SnaX6gNUBHQTeYIH31eIFvfCCneIDy[ZN{\WRiaX6gSZNkcGW{aXPobYEh[2:uaTDCUFIyKGOnbHzzJIF1KDFyIIXNJIFnfGW{IEOgbJJ{KGK7IH\seY9z\XOlZX7j[UBxd2yjcnn6ZZRqd25iY3;tdIV1cXSrb36gZZN{[XluIFvpJF0hOC5\|IN88UU4>	MlfPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF6MEe1NVIoRjJzOEC3OVEzRC:jPh?=
BL21	MVLGeY5kfGmxbjDhd5NigQ>?	MXKxNEB2VQ>?	NXvWc5huOyCqcoO=		MnPpSIl{eGyjY3Xt[Y51KG:oIFLPSGlRYS2EYXugZ49vcnWpYYTl[EBx\XC2aXTlJIZzd21iR2PUMZRi\2enZDDoeY1idiCEY3ytNk1tcWunIIDyc5RmcW5iMTDZNVAyUCCvdYThcpQh\XiycnXzd4VlKGmwIFXzZ4hmemmlaHnhJINwdGliQlyyNUBk\WyuczDheEAyOCC3TTDh[pRmeiB\|IHjyd{BjgSCobIXvdoV{[2WwY3WgdI9t[XKrenH0bY9vKGOxbYDleIl1cW:wIHHzd4F6NCCNaTC9JFAvOzhizszNMi=>	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOThyN{WxNkc,OjF6MEe1NVI9N2F-
BL21 (DE3)	NHfVN4FHfW6ldHnvckBie3OjeR?=		MYqyJIhzew>?		MoTlRolv\GmwZzDh[oZqdmm2eTD0c{BPNXSncn3pcpV{KD[[IFjpd{11[WepZXSgbJVu[W5iQnPsNkBmgHC{ZYPz[YQhcW5iRYPjbIVzcWOqaXGgZ49tcSCETEKxJEhFTTNrIHPlcIx{KGGodHXyJFIhcHK\|IHL5JIZtfW:{ZYPj[Y5k\SCyb3zhdol7[XSrb36gZZN{[XluIFvpJF0hOC5yMEC2JO69VS5?	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjR2OEm4PEc,OjJ2NEi5PFg9N2F-
BL21 (DE3)	MX;GeY5kfGmxbjDhd5NigQ>?		MnTQNkBpenN?		NWnvUnVoSmmwZHnu[{Bi\m[rbnn0fUB1dyCQLYTldo1qdnW\|IEjYJGhqey22YXfn[YQhcHWvYX6gRoNtNXiOIHX4dJJme3OnZDDpckBGe2OqZYLpZ4hq[SClb3zpJGJNOjFiKFTFN{kh[2WubIOgZYZ1\XJiMjDodpMh[nliZnz1c5Jme2OnbnPlJJBwdGG{aYrheIlwdiCjc4PhfUwhU2liPTCwMlAxOSEQvF2u	NYLLRmk4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK0OFg6QDhpPkKyOFQ5QTh6PD;hQi=>
Toledo	NGXCcmFCeG:ydH;zbZMh[XO\|YYm=				NHP2e3pKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m\|IHnuJIh2dWGwIGTvcIVldyClZXzsd{whVER3MDC9JFAvODZizszNMi=>	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlyME[1Nkc,OjR7MEC2OVI9N2F-
KB	NV;1VmVXS3m2b4TvfIlkcXS7IHHzd4F6	MmnnNE42KHWP			MVTDfZRwfG:6aXPpeJkhcW5iaIXtZY4he2mUTlGtcYVlcWG2ZXStUWNNOS2tbnPvb{Bld3ewIFvCJINmdGy\|IH;2[ZJmgHC{ZYPzbY5oKEKFTEKgZZQhOC53IIXN	M{C1PVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6MESwNFQ{Lz5zOEC0NFA1OzxxYU6=
Eu-Myc	M2Kz[mFxd3C2b4Ppd{Bie3OjeR?=	MXexJJVO			Mo\STY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDtc5V{\SCHdT3NfYMh[2WubIOgc5ZmemW6cILld5NqdmdiQlPMNkBie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJINwdG:weTDmc5Ju[XSrb36gZZQhOSC3TR?=	NGS1eYQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEC0NFA1Oyd-MUiwOFAxPDN:L3G+
HeLa	M2DRNWZ2dmO2aX;uJIF{e2G7	NXXleVdnOSC3TR?=	M2DzO\|EzKGi{cx?=		MVjJcoR2[3Srb36gc4YhSmOuLYjMMY1m\GmjdHXkJIFxd3C2b4Ppd{BqdiCmb4j5Z5lkdGmwLYP0bY12dGG2ZXSgbJVu[W5iSHXMZUBk\WyuczDveoVz\XiycnXzd4lv\yCQb4jhJIF1KDFidV2gZYZ1\XJiMUKgbJJ{KGK7IFjv[YNpe3Ric4ThbY5qdmd?	M{DSPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{i2PVgzLz5{MkO4Olk5OjxxYU6=
HeLa	MVfGeY5kfGmxbjDhd5NigQ>?	NUmy[HJGOTBidV2=	MVixOkBpenN?		MYnJcohq[mm2aX;uJI9nKFKudXOtRoF5N2W\RmCtRoNtNXiOIHnueIVz[WO2aX;uJIV5eHKnc4Pl[EBqdiCqdX3hckBJ\UyjIHPlcIx{KGG2IEGwJJVOKGGodHXyJFE3KGi{czDifUBDWkWWIHHzd4F6	NGL2eYg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkSyOVA{OSd-MkK0NlUxOzF:L3G+
MDA-MB-231	MUjGeY5kfGmxbjDhd5NigQ>?	NFGwTmgxNjB\|IITvJFEhfU1?	MXuxJIhz		NWDRfJJRSW62YXfvcol{fCCjY4Tpeol1gSCjdDDy[YNwdWKrbnHueEBD[2xvWFygZZN{\XO\|ZXSgZZMhemW\|dH;yZZRqd25ib3[gRmlOKEKKMz3pcoR2[2WmIGPtZYMheHKxdHXpckBz\WynYYPlJIlvKG2rdH;jbI9v\HKrYTDpd49t[XSnZDDmdo9uKE2GQT3NRk0zOzFiY3XscJMh[XRiMD6wN{B1dyBzIIXNJIFnfGW{IEGgbJIh[nliV3XzeIVzdiCkbH;0JIFv[Wy7c3nz	MkXuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ5NEe1PVgoRjJ{N{S3OVk5RC:jPh?=
MDA-MB-231	NV3uUoQxTnWwY4Tpc44h[XO\|YYm=	M4nJdVAvODNidH:gNUB2VQ>?	NYDN[nM4OSCqch?=		NWPSclNOSW62YXfvcol{fCCjY4Tpeol1gSCjdDDy[YNwdWKrbnHueEBD[2xvWFygZZN{\XO\|ZXSgZZMhemW\|dH;yZZRqd25ib3[gRmlOKEKKMz3pcoR2[2WmIHP5eI9kcHKxbXWgZ{Bz\WynYYPlJIlvKG2rdH;jbI9v\HKrYTDpd49t[XSnZDDmdo9uKE2GQT3NRk0zOzFiY3XscJMh[XRiMD6wN{B1dyBzIIXNJIFnfGW{IEGgbJIh[nliV3XzeIVzdiCkbH;0JIFv[Wy7c3nz	NG\QV2Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mke0O\|U6QCd-MkK3OFc2QTh:L3G+
BP3	MnewRZBweHSxc3nzJIF{e2G7	M360OFExKHWP	MWeyOEBpenN?		MnXITY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDoeY1idiCEUEOgZ4VtdHNiYYSgNVAhfU1iaX7jeYJifGWmIH\vdkAzPCCqcoOgZpkhSW6wZYjpckBXKGGwZDDwdo9xcWSrdX2gbY9lcWSnIIP0ZYlvcW6pIHLhd4VlKE[DQ2OgcYV1cG:m	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzB2N{KyPEc,OjNyNEeyNlg9N2F-
IM9	NF\t[JRCeG:ydH;zbZMh[XO\|YYm=	NV;z[ZpqOTBidV2=	NXrEO4hiOjRiaILz		Mne5TY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDoeY1idiCLTUmgZ4VtdHNiYYSgNVAhfU1iaX7jeYJifGWmIH\vdkAzPCCqcoOgZpkhSW6wZYjpckBXKGGwZDDwdo9xcWSrdX2gbY9lcWSnIIP0ZYlvcW6pIHLhd4VlKE[DQ2OgcYV1cG:m	MnS1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNyNEeyNlgoRjJ\|MES3NlI5RC:jPh?=
RS4:11	MnzYRZBweHSxc3nzJIF{e2G7	NX[xUZVYOTBidV2=	MWCyOEBpenN?		NE\1SFJKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m\|IHnuJIh2dWGwIGLTOFoyOSClZXzsd{BifCBzMDD1UUBqdmO3YnH0[YQh\m:{IEK0JIhzeyCkeTDBco5mgGmwIG[gZY5lKHC{b4Dp[Il2dSCrb3Tp[IUhe3SjaX7pcoch[mG\|ZXSgSmFEWyCvZYToc4Q>	M3PWeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MES3NlI5Lz5{M{C0O\|IzQDxxYU6=
HCT116	NFTk[ZdCeG:ydH;zbZMh[XO\|YYm=		Mn;0OFghcHK\|		MVTJcoR2[3Srb36gc4Yh[XCxcITvd4l{KGmwIHj1cYFvKEiFVEGxOkBxPTNtLzugZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KEGwbnX4bY4hXi2ISWTDJJN1[WmwaX7nMYJie2WmIH\sc5ch[3m2b33leJJq[yCvZYToc4Q>	NX63b\|ZLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[5PFI{PzJpPkK2PVgzOzd{PD;hQi=>
DMS53	NGH0PY9CeG:ydH;zbZMh[XO\|YYm=	M2jsfVUhfG9iMUCgeW0>	M{f6WlEzKGi{cx?=		MXjJcoR2[3Srb36gc4Yh[XCxcITvd4l{KGmwIHj1cYFvKESPU{WzJINmdGy\|IHjhdoJwemmwZzDwOVMhdXW2YX70JIF{e2W\|c3XkJIF{KGO7dH;jbJJwdWViYzDy[Yxm[XOnIHH0JFUhfG9iMUCgeW0h[W[2ZYKgNVIhcHK\|IHL5JIludXWwb3Lsc5R1cW6pIH3leIhw\A>?	M{DjZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4OUiyN\|czLz5{Nkm4NlM4OjxxYU6=
DMS53	MkHQSpVv[3Srb36gZZN{[Xl?	M1TFZlUhfG9iMUCgeW0>	MlrrNVIhcHK\|		M2PsUmlvcGmkaYTpc44hd2ZiQlPsMVIwSmmvIHnueIVz[WO2aX;uJIlvKGi3bXHuJGROWzV\|IHPlcIx{KGijcnLvdolv\yCyNUOgcZV1[W62IHH0JFUhfG9iMUCgeW0h[W[2ZYKgNVIhcHK\|IHL5JIludXWwb4Dy[YNqeGm2YYTpc44hdWW2aH;k	NVHtPFhuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[5PFI{PzJpPkK2PVgzOzd{PD;hQi=>
DMS53	Mm\3RZBweHSxc3nzJIF{e2G7	NVvQNmtoPSC2bzCxNEB2VQ>?	NX3te5pbOTJiaILz		MmjYTY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDoeY1idiCGTWO1N{Bk\WyuczDoZZJjd3KrbnegdFU{KG23dHHueEBie3Onc4Pl[EBieyCSQWLQJINt\WG4YXflJIF1KDVidH:gNVAhfU1iYX\0[ZIhOTJiaILzJIJ6KGmvbYXuc4Jtd3S2aX7nJI1mfGixZB?=	Mo\lQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ7OEKzO\|IoRjJ4OUiyN\|czRC:jPh?=
DMS53	NVjqc2Y2SXCxcITvd4l{KGG\|c3H5	MYK1JJRwKDFyIIXN	MnfiNVIhcHK\|		MVPJcoR2[3Srb36gc4Yh[XCxcITvd4l{KGmwIHj1cYFvKESPU{WzJINmdGy\|IHjhdoJwemmwZzDwOVMhdXW2YX70JIF{e2W\|c3XkJIF{KGOjc4Dhd4UuOyClbHXheoFo\SCjdDC1JJRwKDFyIIXNJIFnfGW{IEGyJIhzeyCkeTDpcY12dm:kbH;0eIlv\yCvZYToc4Q>	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjl6MkO3Nkc,OjZ7OEKzO\|I9N2F-
DMS53	NGn6XGRHfW6ldHnvckBie3OjeR?=	MkPFOUB1dyBzMDD1US=>	MUGxNkBpenN?		MXHJcohq[mm2aX;uJI9nKEKFbD2yM2JigCCrboTldoFkfGmxbjDpckBpfW2jbjDEUXM2OyClZXzsd{Bp[XKkb4LpcocheDV\|IH31eIFvfCCjdDC1JJRwKDFyIIXNJIFnfGW{IEGyJIhzeyCkeTDpcY12dm:ycnXjbZBqfGG2aX;uJI1mfGixZB?=	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjl6MkO3Nkc,OjZ7OEKzO\|I9N2F-
U-2 OS	NVLCR5BFeUiWUzDhd5NigQ>?				MV3xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhXS1{IF;TJINmdGy\|	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
A673	NHL1WpVyUFSVIHHzd4F6				MX3xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSTZ5MzDj[Yxtew>?	NXrzPJp[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
DAOY	MmL4dWhVWyCjc4PhfS=>				M2X0OJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCGQV;ZJINmdGy\|	NWG1UXBnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
Saos-2	MYXxTHRUKGG\|c3H5				MmLvdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFOjb4OtNkBk\Wyucx?=	NYjBUG17RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
RD	Mk[2dWhVWyCjc4PhfS=>				NH24bGtyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUlSgZ4VtdHN?	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
SK-N-SH	NIHEUFRyUFSVIHHzd4F6				NXnRSoloeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGPLMW4uW0hiY3XscJM>	NIXlVJo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
NB1643	M3nmNJFJXFNiYYPzZZk>				NYjUfHNleUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IF7CNVY1OyClZXzsdy=>	NV;HfHNXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
OHS-50	NYPEfZRxeUiWUzDhd5NigQ>?				Mn\VdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE:KUz21NEBk\Wyucx?=	Mo\QQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
LAN-5	Mk\sdWhVWyCjc4PhfS=>				MmexdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgUGFPNTViY3XscJM>	NHLXc4I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
DAOY	MXPxTHRUKGG\|c3H5				NH\KfolyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBFSU:\IHPlcIx{	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
NB-EBc1	NFfIeIdyUFSVIHHzd4F6				NVzFW2l4eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhVkJvRVLjNUBk\Wyucx?=	NEXTSGs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
Rh41	MmnXdWhVWyCjc4PhfS=>				NFzOVlJyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUni0NUBk\Wyucx?=	NYCzcVNFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
A673	Ml62dWhVWyCjc4PhfS=>				MXfxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDBOlc{KGOnbHzzLS=>	NWTxSld6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh30	MnLHdWhVWyCjc4PhfS=>				MnPGdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKqM{CgZ4VtdHN?	M1TBRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
MG 63 (6-TG R)	Mo\jdWhVWyCjc4PhfS=>				NIfIWYFyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBOTyB4MzCoOk1VTyCUKTDj[Yxtew>?	M1;5cFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
U-2 OS	NVnKNW4{eUiWUzDhd5NigQ>?				NGm0VWNyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBWNTJiT2OgZ4VtdHN?	M1TjSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh41	NXXibVVleUiWUzDhd5NigQ>?				MXjxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDSbFQyKGOnbHzz	NUD2OXAyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
SJ-GBM2	M3LJT5FJXFNiYYPzZZk>				MlrMdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFOMLVfCUVIh[2WubIO=	Ml7OQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SK-N-MC	MYTxTHRUKGG\|c3H5				NYjsRpJreUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGPLMW4uVUNiY3XscJM>	NHXXboU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
NB-EBc1	M3LISpFJXFNiYYPzZZk>				MlK1dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE6ELVXCZ\|Eh[2WubIO=	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
LAN-5	MXfxTHRUKGG\|c3H5				MXfxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVEGQLUWgZ4VtdHN?	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Rh18	NHTTXnFyUFSVIHHzd4F6				MYXxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWmhzODDj[Yxtew>?	Ml7JQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
NB1643	MWXxTHRUKGG\|c3H5				MlKwdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgUmIyPjR\|IHPlcIx{	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
SK-N-MC	NW\pfFJIeUiWUzDhd5NigQ>?				M2fRUpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHNMNU5vTVOgZ4VtdHN?	M3\QblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
TC32	NX7RWJpLeUiWUzDhd5NigQ>?				MlLadWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgWGM{OiClZXzsdy=>	NUTBdnhZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh18	MVLxTHRUKGG\|c3H5				NXSybG9HeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhWmhzODDj[Yxtew>?	NULG[FM6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
Saos-2	M{HrNpFJXFNiYYPzZZk>				M3ixfZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHNid3NvMjDj[Yxtew>?	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	PARP / c-PARP / cleaved caspase 3 ; PubMed: 21393866 J Clin Invest H146 cells were preincubated in normoxia or hypoxia (1% O2) for 18 hours prior to treatment with ABT-737 (89.1 nM ), after which cells were harvested for protein analysis by Western blot. Hif-1a; PubMed: 22006676 Mol Cancer Ther Representative western blots for HIF-1α, PARP and cleaved caspase 3 in response to 24-72 hr exposure to ABT-737 in varying concentration in normoxia and hypoxia in 4 neuroblastoma cell lines. Actin is shown as a loading control. Blots are representative of 3 independent experiments. γ-H2AX / p-ATM; PubMed: 21084274 Cancer Res Induction of γ-H2AX and p-ATM by ABT-737. Cells were treated with 10 µmol/L ABT-737 for 24 hours and then maintained in fresh media for 1 or 2 more days prior to Western blot analysis.	21393866 22006676 21084274
Immunofluorescence	cytochrome C; PubMed: 26447615 Oncotarget Immunocytochemistry revealed the release of mitochondrial cytochrome c (green) into the cytoplasm after ABT-737 exposure (20 μM in MC-3 cells and 22.5 μM in HN22 cells) for 24 hr. MitoTracker (red) staining labels mitochondria within each field. Bax; PubMed: 26447615 Oncotarget Immunocytochemistry revealed the mitochondrial translocation of Bax from the cytoplasm after ABT-737 treatment (20 μM in MC-3 cells and 22.5 μM in HN22 cells) for 24 hr. MitoTracker (red) staining labels mitochondria within each field C. To assess whether ABT-737 treatment has an effect on the dimerization of Bax, the levels of dimeric Bax were measured with or without ABT-737 treatment in MC-3 and HN22 cells. Bim; PubMed: 26447615 Oncotarget Immunocytochemistry revealed the mitochondrial translocation of Bim from the cytoplasm after ABT-737 treatment (20 μM in MC-3 cells and 22.5 μM in HN22 cells) for 24 hr. MitoTracker (red) staining labels mitochondria within each field. AIF; PubMed: 25034785 Cell Death Differ localization of apoptosis inducing factor (AIF) in LCSC pre-stained with Mitotracker Red and untreated or treated with 500 nM ABT-737 for 48 h. Magnification × 60, zoom × 3, bar 20 μm. p65 ; PubMed: 28846096 Nat Cell Biol BCL-xL dependent SVEC cells were treated with ABT-737 (10 μM) +/- Q-VD-Oph (30 μM) for 1 h, immunostained for p65 and analysed by confocal microscopy. TNF (20 ng/ml) was used as positive control for p65 nuclear translocation. Scale bar represents 30μM. Representative images from three independent experiments.	26447615 25034785 28846096
Growth inhibition assay	Cell viability; PubMed: 22311987 J Biol Chem Stably transfected K562 cells were treated with increasing concentrations of ABT-737, obatoclax, or maritoclax for 24 h. Cell viability was determined by measuring intracellular ATP levels with the CellTiter Glo assay.	22311987
ELISA	IL-6 / IL-8; PubMed: 21084274 Cancer Res The secretion of IL-6 and IL-8 in PV-10 cells treated with DMSO, ABT-737 or enantiomer for 24 hours was determined by ELISA.	21084274

体内研究

ABT-737按30 mg/kg剂量作用于白血病模型，抑制白血病负担值达53% , 且明显延长鼠寿命。ABT-737不会引起血细胞数和血浆化学性质发生变话。^[1] ABT-737延长移植BCL-2传感肿瘤的鼠寿命。^[2] ABT-737按100 mg/kg剂量作用于ATLL鼠模型具有强抗癌活性。^[5]

激酶实验： ^[1]	- 合并荧光偏振实验: 测定GST-BCL-2蛋白家族与FITC-BIM BH3域结合的亲和力。100 nM GST-BCL-2家族融合蛋白和不同浓度 ABT-737在PBS温育2分钟。然后，加入20 nM FITC-BIM BH3 肽。进行荧光偏振，测定IC50值。
细胞实验： ^[4]	- 合并 Cell lines: SCLC细胞系，包括NCI-H889, NCI-H1963, NCI-H1417, NCI-H146, NCI-187, DMS79, NCI-1048, NCI-H82, NCI-H196, H69AR,和DMS114 Concentrations: 0.001-10 μM Incubation Time: 48小时 Method: SCLC细胞在含10%人血浆的 100 μL 组织培养基的96孔培养板上处理48小时，使用MTS测定存活细胞。 (Only for Reference)
动物实验： ^[1]	- 合并 Animal Models: 注射ER细胞的Scid 鼠 Dosages: 20 mg/kg和30 mg/kg Administration: 腹腔注射 (Only for Reference)

参考文献

- 合并

溶解度 (25°C)

体外	DMSO	100 mg/mL (122.93 mM)
	Water	Insoluble
	Ethanol	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 2%DMSO+40%PEG300+5%Tween80+53%ddH2O	2mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download ABT-737 SDF

分子量	813.43
化学式	C₄₂H₄₅ClN₆O₅S₂
CAS号	852808-04-9
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	N/A

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

常见问题及建议解决方法

问题 1：
What’s the recommended method about reconstitution of the compound for in vivo animal study?
回答：
For oral administration, we suggest the vehicle: 30% Propylene glycol, 5% Tween 80, 65% D5W, at up to 30mg/ml; For injection, ABT-737 can be dissolved in 2% DMSO/50% PEG 300/5% Tween 80/ddH2O at 2.5 mg/ml.

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

选择性强的Bcl-2抑制剂

ABT-199 (GDC-0199) : Bcl-2-selective, K_i<0.01 nM.
活性最高的Bcl-2抑制剂

ABT-263 (Navitoclax) : Bcl-xL, K_i≤ 0.5 nM; Bcl-2, K_i≤ 1 nM; Bcl-w, K_i≤ 1 nM.
用于临床的Bcl-2抑制剂

Obatoclax Mesylate (GX15-070) : Phase II for leukemia, lymphoma, myelofibrosis, and mastocytosis.

研究领域

产品类型

定制您的化合物库

ABT-737

客户使用Selleck生产的ABT-737发表文献317篇：

产品安全说明书

Bcl-2抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download ABT-737 SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

技术支持

常见问题及建议解决方法

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

相关Bcl-2产品